Control of T helper 2 cell function and allergic airway inflammation by PKC
</NOBR><NOBR>Pilar Martin<SUP> *</SUP></NOBR>, <NOBR>Ricardo Villares<SUP>
</SUP></NOBR>, <NOBR>Sandra Rodriguez-Mascarenhas<SUP> *</SUP></NOBR>, <NOBR>Angel Zaballos<SUP>
</SUP></NOBR>, <NOBR>Michael Leitges<SUP>
</SUP></NOBR>, <NOBR>Judit Kovac<SUP>
</SUP></NOBR>, <NOBR>Irene Sizing<SUP>
</SUP></NOBR>, <NOBR>Paul Rennert<SUP>
</SUP></NOBR>, <NOBR>Gabriel M?rquez<SUP>
</SUP></NOBR>, <NOBR>Carlos Mart?nez-A<SUP>
</SUP></NOBR>, <NOBR>Mar?a T. Diaz-Meco<SUP> *</SUP></NOBR>, and <NOBR>Jorge Moscat<SUP> *,</SUP><SUP> ?</SUP></NOBR>
<SUP>*</SUP>Centro de Biolog?a Molecular Severo Ochoa and <SUP>
</SUP>Departamento de Inmunologia y Oncologia-Centro Nacional de Biotecnolog?a, Consejo Superior de Investigaciones Cientificas, Universidad Autonoma de Madrid, Cantoblanco, 28049 Madrid, Spain; <SUP>
</SUP>Max-Planck-Institut f?r Experimentelle Endokrinologie, Feodor-Lynen-Strasse 7, 30625 Hannover, Germany; and <SUP>
</SUP>Biogen, 14 Cambridge Center, Cambridge, MA 02142
Edited by Tak Wah Mak, University of Toronto, Toronto, ON, Canada, and approved May 20, 2005 (received for review February 11, 2005)
<!-- null -->
<TABLE cellSpacing=0 cellPadding=0 width="100%" bgColor=#e1e1e1><TBODY><TR><TD vAlign=center align=left width="5%" bgColor=#ffffff>
</TD><TH vAlign=center align=left width="95%"> Abstract </TH></TR></TBODY></TABLE><TABLE cellPadding=5 align=right border=1><TBODY><TR><TH align=left>
Top
Abstract
Materials and Methods
Results
Discussion
References
</TH></TR></TBODY></TABLE>
Asthma is a disease of chronic airway inflammation in which<SUP> </SUP>T helper (Th) 2 cells play a critical role. The molecular mechanisms<SUP> </SUP>controlling Th2 differentiation and function are of paramount<SUP> </SUP>importance in biology and immunology. PKC
has been implicated<SUP> </SUP>in the regulation of apoptosis and NF-
B, as well as in the control<SUP> </SUP>of T-dependent responses, although no defects were detected<SUP> </SUP>in na?ve T cells from PKC
<SUP>?/?</SUP> mice. Here, we<SUP> </SUP>report that PKC
is critical for IL-4 signaling and Th2 differentiation.<SUP> </SUP>Thus, PKC
levels are increased during Th2 differentiation, but<SUP> </SUP>not Th1 differentiation, of CD4<SUP>+</SUP> T cells, and the loss of PKC
<SUP> </SUP>impairs the secretion of Th2 cytokines in vitro and in vivo,<SUP> </SUP>as well as the nuclear translocation and tyrosine phosphorylation<SUP> </SUP>of Stat6 and Jak1 activation, essential downstream targets of<SUP> </SUP>IL-4 signaling. Moreover, PKC
<SUP>?/?</SUP> mice display dramatic<SUP> </SUP>inhibition of ovalbumin-induced allergic airway disease, strongly<SUP> </SUP>suggesting that PKC
can be a therapeutic target in asthma.<SUP> </SUP>
apoptosis | asthma | NF-
B
<HR align=center width="50%" noShade SIZE=1>Asthma is a chronic lung inflammatory disease with increased<SUP> </SUP>prevalence in developed countries. The pathology of asthma is<SUP> </SUP>associated with aberrant activation of CD4<SUP>+</SUP> lymphocytes differentiated<SUP> </SUP>along the T helper (Th) 2 lineage (1). Na?ve CD4<SUP>+</SUP> Th cells<SUP> </SUP>can differentiate in response to antigen stimulation into two<SUP> </SUP>distinct subsets of effector cells, Th1 and Th2, which display<SUP> </SUP>distinct cytokine profiles and immune regulatory functions (2).<SUP> </SUP>Th1 cells mainly produce IFN-
and IL-2 and are essential for<SUP> </SUP>cell-mediated immune responses against intracellular pathogens.<SUP> </SUP>Th2 cells produce a different set of cytokines, including IL-4,<SUP> </SUP>IL-5, IL-10, and IL-13, and are important in the control of<SUP> </SUP>humoral immunity and allergy (3). The signaling pathways controlling<SUP> </SUP>Th2 differentiation and function have been the focus of intense<SUP> </SUP>research because they could help to identify therapeutic targets<SUP> </SUP>for asthma and other allergic pathologies. IL-4 is important<SUP> </SUP>for induction and maintenance of differentiated Th2 cells and<SUP> </SUP>for B cell Ig isotype switching to IgE in mice (4). IL-4 and<SUP> </SUP>IL-13 share interactions with the IL-4R
chain and activate the<SUP> </SUP>transcription factor Stat6 through a Jak1/Jak3 signaling pathway<SUP> </SUP>(3, 5).<SUP> </SUP>
The role of the different PKC isoforms in lymphocyte activation<SUP> </SUP>and differentiation is a matter of great interest. The recent<SUP> </SUP>generation of mutant mice in which different PKC isotypes have<SUP> </SUP>been genetically inactivated reveals the selective involvement<SUP> </SUP>of each PKC isoform in cell-specific aspects of the immune response<SUP> </SUP>(6). The characterization of knockout mice for the diacylglycerol-insensitive<SUP> </SUP>atypical PKC
isoform reveals an important role of this kinase<SUP> </SUP>in the immune system (7). Thus, PKC
<SUP>?/?</SUP> adult mice<SUP> </SUP>are unable to mount an optimal immune response (8), suggesting<SUP> </SUP>alterations in lymphocyte function. Although the humoral response<SUP> </SUP>to a T-independent antigen was reduced in the PKC
<SUP>?/?</SUP><SUP> </SUP>mice, the major defects were found in mice challenged with a<SUP> </SUP>T-dependent antigen, specifically, in the levels of IgG1, IgG2a,<SUP> </SUP>and IgG2b (8). Also, basal IgE levels were dramatically reduced<SUP> </SUP>in PKC
<SUP>?/?</SUP> mice compared with WT controls (8), indicating<SUP> </SUP>that some kind of T cell alteration, possibly in the Th2 lineage,<SUP> </SUP>might be produced by the loss of PKC
. Surprisingly, although<SUP> </SUP>the ability of B cells to proliferate in response to B cell<SUP> </SUP>receptor challenge was reproducibly impaired in the PKC
-deficient<SUP> </SUP>mice, no major alterations were observed in the proliferation<SUP> </SUP>of na?ve T cells (8). However, the potential role of PKC
<SUP> </SUP>in Th2 function and asthma had not been addressed previously.<SUP> </SUP>
<!-- null -->
<TABLE cellSpacing=0 cellPadding=0 width="100%" bgColor=#e1e1e1><TBODY><TR><TD vAlign=center align=left width="5%" bgColor=#ffffff>
</TD><TH vAlign=center align=left width="95%"> Materials and Methods </TH></TR></TBODY></TABLE><TABLE cellPadding=5 align=right border=1><TBODY><TR><TH align=left>
Top
Abstract
Materials and Methods
Results
Discussion
References
</TH></TR></TBODY></TABLE>
Mice. PKC
<SUP>?/?</SUP> and WT mice (SV129J background) are<SUP> </SUP>described in ref. 7. Mice aged between 6 and 8 weeks were used<SUP> </SUP>for the in vitro experiments. Age- and sex-matched 10- to 12-week-old<SUP> </SUP>mice were used for the in vivo asthma model.<SUP> </SUP>
Antibodies and Reagents. Antibodies to murine CD3
(145-2C11)<SUP> </SUP>and CD28 (37.51) and biotinylated CD8
(53-6.7), CD11b (Mac-1),<SUP> </SUP>CD16 (2.4G2), CD19 (1D3), CD24 (M1/69), CD62L (MEL-14), CD117<SUP> </SUP>(2B8), B220 (RA3-6B2), and CD4-FITC (L3T4) as well as IL-4-phycoerythrin<SUP> </SUP>(PE) and CD25-PE (PC61) were from Pharmingen. Antibodies to<SUP> </SUP>Stat6 (S-20), phospho-extracellular signal-regulated kinase<SUP> </SUP>(ERK) (E-4), ERK1 (K-23), phospholipase C-
(Y783), GATA3 (HG3?31),<SUP> </SUP>c-Maf (M-153), actin (I-19), T-bet (4B10), proliferating cell<SUP> </SUP>nuclear antigen (FL-261), and nuclear factor of activated T<SUP> </SUP>cells (NFAT) c1 (7A6) were from Santa Cruz Biotechnology. Stat5,<SUP> </SUP>Jak1, phospho-Stat6 (Tyr-641), phospho-Stat5 (Y694), and phospho-Jak1<SUP> </SUP>(Tyr-1022 and Tyr-1023) antibodies were from Cell Signaling<SUP> </SUP>Technology (Beverly, MA). Recombinant murine IL-2, IL-12, and<SUP> </SUP>IL-4 as well as anti-IFN-
, anti-IL-5, anti-IL-4R
, and anti-IL-4<SUP> </SUP>antibodies were from <!--ad-->R & D Systems. IFN-
, IL-4, IL-5, and<SUP> </SUP>IL-10 ELISA kits were from Pharmingen, and the IL-13 ELISA kit<SUP> </SUP>was from <!--ad-->R & D Systems. Specific polyclonal anti-PKC
antibody<SUP> </SUP>was generated against the sequence encompassing amino acids<SUP> </SUP>185?244 of PKC
.<SUP> </SUP>
CD4<SUP>+</SUP> T Cell Isolation and Differentiation. To obtain na?ve<SUP> </SUP>CD4<SUP>+</SUP> T cells, single cell suspensions were prepared from spleens<SUP> </SUP>and mesenteric lymph nodes of the indicated mice and were incubated<SUP> </SUP>with biotinylated antibodies directed at CD8, CD16, CD19, CD24,<SUP> </SUP>CD117, major histocompatibility complex class II (I-A<SUP>b</SUP>), and<SUP> </SUP>CD11b followed by incubation with anti-biotin-conjugated microbeads.<SUP> </SUP>Na?ve CD4<SUP>+</SUP> T cells were negatively selected in an autoMACS<SUP> </SUP>separator (Miltenyi Biotec, Auburn, CA) according to the manufacturer's<SUP> </SUP>instructions. Purified CD4<SUP>+</SUP> T cells were labeled with antibodies<SUP> </SUP>specific for CD4, CD25, CD62L, and B220 and analyzed by flow<SUP> </SUP>cytometry to confirm purity and the na?ve status (Fig.<SUP> </SUP>6, which is published as supporting information on the PNAS<SUP> </SUP>web site). Na?ve CD4<SUP>+</SUP> T cells (10<SUP>6</SUP> cells per ml) were differentiated<SUP> </SUP>in the presence of irradiated antigen-presenting cells (10<SUP>6</SUP><SUP> </SUP>cells per ml), immobilized anti-CD3 (1 ?g/ml), and IL-2<SUP> </SUP>(10 ng/ml). For Th0 cultures, anti IL-4 (4 ?g/ml) and<SUP> </SUP>anti-IFN-
(4 ?g/ml) were added. For Th1 differentiation,<SUP> </SUP>IL-12 (3.5 ng/ml) and anti-IL-4 (4 ?g/ml) were added to<SUP> </SUP>the culture, whereas IL-4 (4 ng/ml) and anti-IFN-
(4 ?g/ml)<SUP> </SUP>were added for Th2 differentiation. After 4 days, the cells<SUP> </SUP>were extensively washed, counted, and restimulated as described.<SUP> </SUP>No differences in viability were observed in WT and knockout<SUP> </SUP>na?ve Th0, Th1, or Th2 cells.<SUP> </SUP>
FACS Analysis and Intracellular Staining. GATA3 protein levels<SUP> </SUP>were assessed by intracellular staining in cells fixed overnight<SUP> </SUP>with 70% ethanol at ?20?C and stained with anti-GATA3<SUP> </SUP>or control mouse IgG1 followed by FITC-anti-mouse IgG1. To determine<SUP> </SUP>intracellular IL-4 levels, brefeldin A (BD GolgiPlug, BD Biosciences)<SUP> </SUP>was added 4 h before harvest to Th2 polarized WT and PKC
<SUP>?/?</SUP><SUP> </SUP>cells that had been restimulated for 48 h with anti-CD3 in the<SUP> </SUP>absence or presence of anti-CD28. Afterward, cells were fixed<SUP> </SUP>and permeabilized by using the BD Cytofix/Cytoperm kit (BD Biosciences)<SUP> </SUP>and stained with anti-IL-4-phycoerythrin. Analysis was performed<SUP> </SUP>in a FACSCalibur cell sorter (BD Biosciences) with CELLQUESTPRO<SUP> </SUP>software.<SUP> </SUP>
PKC
Kinase Assay. Cell extracts prepared in lysis buffer (50<SUP> </SUP>mM Tris?HCl, pH 7.5/150 mM NaCl/1 mM EGTA/2 mM EDTA/1%<SUP> </SUP>Triton X-100) were immunoprecipitated with the specific anti-PKC
<SUP> </SUP>antibody that does not crossreact with PKC
/
for2hat4?C.<SUP> </SUP>Immunoprecipitates were captured with protein A and washed extensively<SUP> </SUP>in lysis buffer with 0.5 M NaCl. The enzymatic assay was carried<SUP> </SUP>out in the immunoprecipitates in assay buffer [35 mM Tris?HCl,<SUP> </SUP>pH 7.5/10 mM MgCl<SUB>2</SUB>/100 ?M CaCl<SUB>2</SUB>/0.5 mM EGTA/100 ?M<SUP> </SUP>ATP/5 ?Ci (1 Ci = 37 GBq) of [<SUP>32</SUP>P]ATP] with 4 ?g<SUP> </SUP>of myelin basic protein as substrate for 1 h at 30?C.<SUP> </SUP>
Cytokine Assays. Na?ve CD4<SUP>+</SUP> T cells were stimulated for<SUP> </SUP>72 h with anti-CD3 (10 ?g/ml) plus anti-CD28 (5 ?g/ml),<SUP> </SUP>and Th2-differentiated cells were restimulated for 24 h with<SUP> </SUP>anti-CD3 (10 ?g/ml), after which, supernatants were collected<SUP> </SUP>and cytokine concentrations were measured by ELISA using commercially<SUP> </SUP>available kits. ELISA was also used to determine the levels<SUP> </SUP>of Th2 cytokines in bronchoalveolar lavage (BAL) fluids.<SUP> </SUP>
Immunofluorescent Analysis. Th2 cells (2 x 10<SUP>5</SUP>) were applied<SUP> </SUP>to glass slides by cytocentrifugation. Cells were fixed, permeabilized<SUP> </SUP>with 0.1% Triton X-100, and incubated with the different antibodies<SUP> </SUP>for 1 h at 37?C and the tetramethylfluorescein tyramide<SUP> </SUP>TSA-Direct amplification system (NEN). For the nuclear staining,<SUP> </SUP>cells were incubated with TO-PRO. Glass coverslips were mounted<SUP> </SUP>on Mowiol and examined with an MRC 1024 confocal system (Bio-Rad)<SUP> </SUP>mounted on an Axiovert 135 microscope (<!--ad-->Zeiss).<SUP> </SUP>
Ovalbumin (OVA)-Induced Allergic Airway Disease. PKC
<SUP>?/?</SUP><SUP> </SUP>and WT mice (10?12 weeks old) were immunized as described<SUP> </SUP>in ref. 9. Briefly, on day 0, 15 ?g of OVA (Sigma) in<SUP> </SUP>200 ?l of alum (Pierce) were injected i.p. into sensitized<SUP> </SUP>mice. On day 5, the animals received another i.p. injection<SUP> </SUP>of 15 ?g of OVA in 200 ?g of alum and, on day 12,<SUP> </SUP>mice were challenged with aerosolized 0.5% OVA in PBS (two challenges<SUP> </SUP>of 60 min each that were 4 h apart). Control animals were aerosolized<SUP> </SUP>with PBS. On day 14, 40 h after the second OVA challenge, mice<SUP> </SUP>were killed for analysis. For histological analysis, lungs from<SUP> </SUP>PBS- or OVA-treated mice were inflated through the trachea with<SUP> </SUP>50% Jung tissue-freezing medium (Leica, Vienna) in PBS. The<SUP> </SUP>right caudal lobe was trimmed, embedded, frozen, and stored<SUP> </SUP>at ?80?C. For the adoptive transfer experiments, WT<SUP> </SUP>and PKC
<SUP>?/?</SUP> mice were i.p. injected with 100 ?g<SUP> </SUP>of OVA in 2 mg of alum, and, 5 days later, spleens and mesenteric<SUP> </SUP>lymph nodes were removed for CD4<SUP>+</SUP> T cell isolation and were<SUP> </SUP>cultured for Th2 differentiation for 4 days with irradiated<SUP> </SUP>antigen-presenting cells, OVA (50 ?g/ml), IL-2 (10 ng/ml),<SUP> </SUP>IL-4 (10 ng/ml), and anti-IFN-
(10 ?g/ml). Afterward,<SUP> </SUP>Th2-like cells were collected, washed, and i.v. injected into<SUP> </SUP>WT and PKC
<SUP>?/?</SUP> recipient mice, which, 24 h later,<SUP> </SUP>were exposed to inhaled 1% OVA in PBS for a total of 7 days<SUP> </SUP>(4 consecutive days exposed, 2 days rested, and 3 consecutive<SUP> </SUP>days exposed) for 20 min daily. Mice were killed 24 h after<SUP> </SUP>the final exposure to antigen, and histological analysis of<SUP> </SUP>lungs was performed. The appropriate institutional animal use<SUP> </SUP>and care committees approved all animal experiments.<SUP> </SUP>
Statistical Analysis. Statistical analyses were performed by<SUP> </SUP>using Student's t test. P < 0.05 was considered to be significant.<SUP> </SUP>
<!-- null -->
<TABLE cellSpacing=0 cellPadding=0 width="100%" bgColor=#e1e1e1><TBODY><TR><TD vAlign=center align=left width="5%" bgColor=#ffffff>
</TD><TH vAlign=center align=left width="95%"> Results </TH></TR></TBODY></TABLE><TABLE cellPadding=5 align=right border=1><TBODY><TR><TH align=left>
Top
Abstract
Materials and Methods
Results
Discussion
References
</TH></TR></TBODY></TABLE>
Impaired Th2 Differentiation in PKC
<SUP>?/?</SUP> Mice. To<SUP> </SUP>determine whether PKC
may play a role in lineage commitment<SUP> </SUP>of CD4<SUP>+</SUP> T helper cells, we initially differentiated CD4<SUP>+</SUP> T cells,<SUP> </SUP>either WT or PKC
<SUP>?/?</SUP>, in vitro under Th1 or Th2 polarizing<SUP> </SUP>conditions, after which, cells were stimulated with anti-CD3<SUP> </SUP>antibody for 48 h, and the secretion of IFN-
and IL-4 was determined<SUP> </SUP>in the Th1 and Th2 cultures, respectively. Results in Fig. 1a<SUP> </SUP>show that whereas IFN-
secretion is not affected, IL-4 is significantly<SUP> </SUP>reduced in PKC
<SUP>?/?</SUP> cells (Fig. 1a). The synthesis<SUP> </SUP>of three other Th2 cytokines, IL-5, IL-10, and IL-13, was also<SUP> </SUP>dramatically inhibited in PKC
<SUP>?/?</SUP> Th2 cells (Fig.<SUP> </SUP>1a). When the levels of intracellular IL-4 were determined in<SUP> </SUP>the presence of brefeldin A by FACS analysis, it was clear that<SUP> </SUP>WT Th2 cells produce significantly more IL-4 than do PKC
<SUP>?/?</SUP><SUP> </SUP>Th2 cells (Fig. 1b), consistent with the ELISA data in Fig.<SUP> </SUP>1a. Together, these results suggest that PKC
plays a nonredundant<SUP> </SUP>role in Th2-polarized CD4<SUP>+</SUP> T cells.<SUP> </SUP>
GATA3 expression is a widely established hallmark of the Th2<SUP> </SUP>polarization process (10). Therefore, we initially analyzed<SUP> </SUP>by using flow cytometry the levels of this transcription factor<SUP> </SUP>in CD4<SUP>+</SUP> T cells incubated under Th0, Th1, and Th2 polarizing<SUP> </SUP>conditions. Interestingly, the loss of PKC
significantly reduces<SUP> </SUP>GATA3 expression in Th2 cells (Fig. 2a), strongly suggesting<SUP> </SUP>that PKC
plays an important role during Th2 differentiation.<SUP> </SUP>Consistent with this notion, the levels of GATA3, as well as<SUP> </SUP>the levels of Stat6, c-Maf, RelA, and NFATc1, were dramatically<SUP> </SUP>reduced in PKC
-deficient Th2 cells as determined by immunoblotting<SUP> </SUP>(Fig. 2b). Interestingly, when Th2-polarized T cells were rechallenged<SUP> </SUP>with anti-CD3 plus anti-CD28, the nuclear levels of all of the<SUP> </SUP>transcription factors tested were likewise inhibited in the<SUP> </SUP>PKC
<SUP>?/?</SUP> cells (Fig. 2c). Therefore, it seems that<SUP> </SUP>PKC
is required for the Th2 differentiation process to properly<SUP> </SUP>occur and for Th2-polarized cells to respond to an anti-CD3<SUP> </SUP>rechallenge.<SUP> </SUP>
Signaling Cascades Inhibited in PKC
<SUP>?/?</SUP> T Cells Induced<SUP> </SUP>to Differentiate Along the Th2 Pathway. Because PKC
appears<SUP> </SUP>to be important for Th2 polarization, we next sought to determine<SUP> </SUP>whether this kinase is induced during this important differentiation<SUP> </SUP>process. First, we generated a polyclonal antibody that selectively<SUP> </SUP>recognizes PKC
and that does not crossreact with PKC
/
. The result<SUP> </SUP>in Fig. 3a shows the specificity of this antibody in immunoblot<SUP> </SUP>analysis of lung extracts, a tissue particularly rich in PKC
<SUP> </SUP>(7), from WT and PKC
<SUP>?/?</SUP> mice. Immunoblotting with<SUP> </SUP>an anti-PKC
/
-specific antibody of the same extracts reveals<SUP> </SUP>that the levels of this aPKC isoform were not affected by the<SUP> </SUP>loss of PKC
(Fig. 3a). Therefore, we next prepared extracts<SUP> </SUP>from CD4<SUP>+</SUP> T cells incubated under Th0, Th1, or Th2 conditions,<SUP> </SUP>and the expression of PKC
was determined by immunoblotting with<SUP> </SUP>our selective antibody. The data in Fig. 3b demonstrate that<SUP> </SUP>PKC
levels are increased under Th2 polarizing conditions, but<SUP> </SUP>not under Th1 polarizing conditions. Immunoblotting with anti-GATA3<SUP> </SUP>and anti-T-bet demonstrated that cells were properly polarized<SUP> </SUP>to the Th2 and Th1 lineages, respectively (Fig. 3b). To determine<SUP> </SUP>whether this induced PKC
is enzymatically active, we immunoprecipitated<SUP> </SUP>this kinase from polarized CD4<SUP>+</SUP> T cell extracts, and the enzymatic<SUP> </SUP>activity was determined in a standard kinase assay. The data<SUP> </SUP>in Fig. 3b show that the activity of PKC
is pronouncedly induced<SUP> </SUP>in Th2 cells.<SUP> </SUP>
<SUP></SUP>
<!-- null -->
<CENTER><TABLE cellSpacing=0 cellPadding=0 width="95%"><TBODY><TR bgColor=#e1e1e1><TD><TABLE cellSpacing=2 cellPadding=2><TBODY><TR bgColor=#e1e1e1><TD vAlign=top align=middle bgColor=#ffffff>
View larger version (24K):
<NOBR>[in this window]
[in a new window]
</NOBR> </TD><TD vAlign=top align=left>Fig. 1. Role of PKC
in Th2 differentiation and cytokine synthesis. (a) Secretion of IFN-
in Th1 cells or IL-5, IL-4, IL-13, and IL-10 in Th2 cells in WT or PKC
<SUP>?/?</SUP> (KO) mice stimulated with anti-CD3 was determined by ELISA. (b) IL-4 intracellular staining of Th2 cells in WT or PKC
<SUP>?/?</SUP> (KO) mice either untreated or treated with anti-CD3 alone or in combination with anti-CD28. Inset numbers represent the percentage of IL-4-positive cells. The results in a are the mean ? SD of three independent experiments with incubations in triplicate. The results in b are representative of another two experiments. ***, P < 0.001.
</TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></CENTER><SUP></SUP>
<!-- null -->
<CENTER><TABLE cellSpacing=0 cellPadding=0 width="95%"><TBODY><TR bgColor=#e1e1e1><TD><TABLE cellSpacing=2 cellPadding=2><TBODY><TR bgColor=#e1e1e1><TD vAlign=top align=middle bgColor=#ffffff>
View larger version (40K):
<NOBR>[in this window]
[in a new window]
</NOBR> </TD><TD vAlign=top align=left>Fig. 2. Th2 transcription factors in PKC
<SUP>?/?</SUP> cells. (a) Intracellular staining of GATA3 in Th0, Th1, and Th2 cells in WT or PKC
<SUP>?/?</SUP> (KO) mice. The solid line represents GATA3 staining; the dashed line corresponds to the mouse IgG1 isotype control. Inset numbers represent the percentage of GATA3-positive cells. (b and c) Western blot analysis of nuclear levels of GATA3, Stat6, RelA, c-Maf, and NFATc1 in cell cultures as above (b) or in Th2 cells stimulated with anti-CD3 plus anti-CD28 (c). Anti-proliferating cell nuclear antigen was used as a loading control in b and c. The results are representative of three independent experiments.
</TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></CENTER>Based on these observations and the impairment of Th2 differentiation<SUP> </SUP>and function of PKC
<SUP>?/?</SUP> T cells, we considered it<SUP> </SUP>important to determine whether PKC
is activated in Th2 cells<SUP> </SUP>upon T cell receptor (TCR) activation. Thus, CD4<SUP>+</SUP> T cells polarized<SUP> </SUP>under Th2 conditions were incubated with anti-CD3, and, afterward,<SUP> </SUP>PKC
enzymatic activity was determined as above. The incubation<SUP> </SUP>with anti-CD3 triggers a dramatic increase in PKC
activity (Fig.<SUP> </SUP>3c) without appreciable changes in the levels of the enzyme<SUP> </SUP>(Fig. 3c). Collectively, these results indicate that PKC
is<SUP> </SUP>activated when Th2-polarized CD4<SUP>+</SUP> T cells are rechallenged with<SUP> </SUP>anti-CD3. Th differentiation is modulated by signals emanating<SUP> </SUP>from the TCR and the cytokines generated during this polarization<SUP> </SUP>process, particularly IL-4, which is present in the culture<SUP> </SUP>medium of CD4<SUP>+</SUP> T cells induced to differentiate to the Th2 lineage.<SUP> </SUP>Importantly, IL-4 is synthesized by Th2 cells when rechallenged<SUP> </SUP>with an anti-CD3 antibody in the absence of any exogenous cytokine,<SUP> </SUP>which exerts a positive feedback activation loop (11). To determine<SUP> </SUP>whether PKC
activation in CD3-triggered CD4<SUP>+</SUP> T cells polarized<SUP> </SUP>under Th2 conditions is a direct effect of TCR signaling or<SUP> </SUP>whether it is mediated by the secreted IL-4, WT CD4<SUP>+</SUP> Th2 cells<SUP> </SUP>activated with anti-CD3 were incubated in the presence of either<SUP> </SUP>neutralizing anti-IL-4 or anti-IL-5 antibodies, after which,<SUP> </SUP>PKC
activity was determined as above. According to the results<SUP> </SUP>of Fig. 3c, PKC
activation by anti-CD3 is dramatically inhibited<SUP> </SUP>by the presence of anti-IL-4 but not by the presence of anti-IL-5<SUP> </SUP>(Fig. 3c). These results indicate that IL-4 is responsible for<SUP> </SUP>the activation of PKC
in CD3-restimulated Th2 cells and that<SUP> </SUP>PKC
could be part of the IL-4 signaling machinery but that it<SUP> </SUP>is not a direct step in the TCR signal transduction cascade.<SUP> </SUP>To address this point, na?ve CD4<SUP>+</SUP> T cells were incubated<SUP> </SUP>with IL-4 for different times, and PKC
enzymatic activity was<SUP> </SUP>determined as above. Interestingly, the addition of IL-4 provokes<SUP> </SUP>a reproducible and robust activation of PKC
in these cells (Fig.<SUP> </SUP>3d), demonstrating that PKC
constitutes a potentially important<SUP> </SUP>step in IL-4 signaling. If this model is correct, that would<SUP> </SUP>imply that the activation of signaling cascades of the TCR should<SUP> </SUP>not be impaired in the PKC
<SUP>?/?</SUP> na?ve CD4<SUP>+</SUP> T<SUP> </SUP>cells but that the stimulation of the IL-4 pathway should be<SUP> </SUP>inhibited. To address this point, we incubated na?ve WT<SUP> </SUP>and PKC
<SUP>?/?</SUP> CD4<SUP>+</SUP> T cells with or without IL-4, after<SUP> </SUP>which, tyrosine phosphorylation of Stat6 and Jak1 was determined<SUP> </SUP>by immunoblotting with phospho-site-specific antibodies. Results<SUP> </SUP>in Fig. 3e Left demonstrate that the loss of PKC
dramatically<SUP> </SUP>impairs the activation of Stat6 and Jak1 in na?ve CD4<SUP>+</SUP><SUP> </SUP>T cells. However, the loss of PKC
does not affect the activation<SUP> </SUP>of ERK or NFATc1 (Fig. 3f) or that of NF-
B (Fig. 3g) or I
B kinase<SUP> </SUP>activity (Fig. 3h) in these cells when stimulated with anti-CD3<SUP> </SUP>plus anti-CD28. The secretion of IL-4 and IL-5 in na?ve<SUP> </SUP>CD4<SUP>+</SUP> T cells activated with anti-CD3 is normal in the PKC
<SUP>?/?</SUP><SUP> </SUP>cells (Fig. 3i), reinforcing the notion that PKC
is not a direct<SUP> </SUP>target of TCR signaling. Likewise, the loss of PKC
did not affect<SUP> </SUP>IL-2-induced Stat5 activation in this system (Fig. 3e Right).<SUP> </SUP>Taken together, these results suggest that the defect in Th2-polarized<SUP> </SUP>cells is accounted for by the important role played by PKC
in<SUP> </SUP>IL-4 signaling but not in TCR downstream events. This model<SUP> </SUP>is consistent with our previously published results that demonstrated<SUP> </SUP>the lack of defects in the proliferation of na?ve T cells<SUP> </SUP>from PKC
<SUP>?/?</SUP> mice, a phenomenon that is clearly dependent<SUP> </SUP>on IL-2 production and signaling (8). In contrast, because the<SUP> </SUP>common
-chain receptor is essential for IL-2 and IL-4 function,<SUP> </SUP>the fact that IL-2 signaling is intact in the PKC
<SUP>?/?</SUP><SUP> </SUP>mice (Fig. 3e Right) indicates that the defects observed in<SUP> </SUP>the IL-4 pathway cannot be explained by potential alterations<SUP> </SUP>in the levels of this receptor subunit. In addition, the data<SUP> </SUP>in Fig. 7, which is published as supporting information on the<SUP> </SUP>PNAS web site, demonstrate that the levels of the
-chain of<SUP> </SUP>the IL-4 receptor are intact in na?ve and Th2-polarized<SUP> </SUP>T cells as demonstrated by FACS analysis to detect surface expression<SUP> </SUP>of the receptor (Fig. 1a) and immunoblotting (Fig. 1b). Interestingly,<SUP> </SUP>the nuclear translocation of activated Stat6 is dramatically<SUP> </SUP>inhibited in the PKC
<SUP>?/?</SUP> Th2 cells (Fig. 4a), and<SUP> </SUP>the exogenous addition of IL-4 does not bypass this blockade<SUP> </SUP>(Fig. 4b). These results are consistent with the notion that<SUP> </SUP>PKC
is required for the efficient activation of Jak1 and the<SUP> </SUP>subsequent phosphorylation and nuclear translocation of Stat6.<SUP> </SUP>
<SUP></SUP>
<!-- null -->
<CENTER><TABLE cellSpacing=0 cellPadding=0 width="95%"><TBODY><TR bgColor=#e1e1e1><TD><TABLE cellSpacing=2 cellPadding=2><TBODY><TR bgColor=#e1e1e1><TD vAlign=top align=middle bgColor=#ffffff>
View larger version (35K):
<NOBR>[in this window]
[in a new window]
</NOBR> </TD><TD vAlign=top align=left>Fig. 3. Biochemical signaling pathways in PKC
<SUP>?/?</SUP> cells. (a) Western blot analysis of PKC
and PKC
/
in lung from WT and PKC
<SUP>?/?</SUP> (KO) mice. (b) Extracts from CD4<SUP>+</SUP> T cells incubated under Th0, Th1, or Th2 polarizing conditions were analyzed by immunoblotting for PKC
, GATA3, and T-bet expression and by PKC
kinase activity (KA). (c) WT Th2-polarized T cells were incubated with or without anti-CD3 in the presence or absence of neutralizing anti-IL-4 or anti-IL-5 antibodies, and PKC
kinase activity (KA) and PKC
levels were determined. (d) PKC
kinase activity (KA) and PKC
levels were measured in Th2-polarized cells stimulated with IL-4 for different times. (e) Na?ve CD4<SUP>+</SUP> T cells were stimulated or not stimulated with IL-4 or IL-2 for 10 min; afterward, phospho-Stat6, phospho-Jak1, and phospho-Stat5 levels, as well as levels of Stat6, Jak1, and Stat5, were determined by immunoblotting. (f) Western blot analysis of phospho-ERK, ERK, and NFATc1 in na?ve CD4<SUP>+</SUP> T cells stimulated with anti-CD3 plus anti-CD28. (g) NF-
B activation was analyzed by EMSA in nuclear extracts prepared from na?ve CD4<SUP>+</SUP> T cells stimulated with anti-CD3 plus anti-CD28. (h) I
B kinase activity was determined in the above extracts. The results are representative of three independent experiments. (i) Cytokine production of IL-4 and IL-5 analyzed by ELISA in na?ve CD4<SUP>+</SUP> T cells, either WT or PKC
<SUP>?/?</SUP> (KO), stimulated with anti-CD3 plus anti-CD28. The results are the mean ? SD of three independent experiments with incubations in triplicate.
</TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></CENTER>Loss of PKC
Inhibits Allergic Airway Disease. It is well established<SUP> </SUP>that the Th2 immune response is responsible of the development<SUP> </SUP>of allergic airway inflammation (12?15). Because the loss<SUP> </SUP>of PKC
results in impaired Th2 activation, we reasoned that<SUP> </SUP>PKC
<SUP>?/?</SUP> mice would display reduced inflammatory response<SUP> </SUP>in a model of OVA-induced allergic airway disease that predominantly<SUP> </SUP>generates a Th2 response. Therefore, mice that are either WT<SUP> </SUP>or PKC
<SUP>?/?</SUP> were sensitized to OVA and then challenged<SUP> </SUP>twice with aerosolized antigen or PBS on the same day. Forty-eight<SUP> </SUP>hours after the aerosol challenge, mice were killed, the lungs<SUP> </SUP>were examined histologically by hematoxylin/eosin (H&E)<SUP> </SUP>staining for eosinophilic infiltration, and BAL was performed<SUP> </SUP>to determine inflammatory cell recruitment. There was a robust<SUP> </SUP>increase in total BAL cell numbers in WT mice that were OVA<SUP> </SUP>sensitized and challenged with aerosolized antigen compared<SUP> </SUP>with PBS-challenged mice (Fig. 5a Left), due especially to eosinophils<SUP> </SUP>(Fig. 5a Right). However, this increase was dramatically reduced<SUP> </SUP>in the PKC
<SUP>?/?</SUP> mice (Fig. 5a), indicating that the<SUP> </SUP>impairment in the Th2 response observed in these mutant mice<SUP> </SUP>inhibits airway inflammation. Consistent with this notion, H&E<SUP> </SUP>histological analysis of lung sections from this experiment<SUP> </SUP>shows that whereas the challenged WT mice display a prominent<SUP> </SUP>inflammatory response with massive perivascular and peribronchial<SUP> </SUP>infiltration with abundant eosinophils, PKC
<SUP>?/?</SUP> mice<SUP> </SUP>display a much more attenuated response (Fig. 5b). CD11b staining<SUP> </SUP>confirms a dramatic reduction in granulocyte infiltration in<SUP> </SUP>the OVA-challenged PKC
<SUP>?/?</SUP> mice (Fig. 5c). The production<SUP> </SUP>of mucus in asthmatic patients is severely debilitating and<SUP> </SUP>may lead to death. Periodic acid Schiff's base staining of lung<SUP> </SUP>sections consistently showed mucus production in the airway<SUP> </SUP>epithelium and alveoli of WT mice. In contrast, and concurring<SUP> </SUP>with the milder allergic response to the OVA challenge observed<SUP> </SUP>in the PKC
<SUP>?/?</SUP> mice, mucus production was not observed<SUP> </SUP>in lung sections from these animals (data not shown). In addition,<SUP> </SUP>BAL IL-4, IL-5, IL-13, and eotaxin (Fig. 5d) supernatant levels,<SUP> </SUP>which were dramatically increased in OVA-challenged WT mice,<SUP> </SUP>were severely reduced in similarly treated PKC
<SUP>?/?</SUP><SUP> </SUP>mice.<SUP> </SUP>
<SUP></SUP>
<!-- null -->
<CENTER><TABLE cellSpacing=0 cellPadding=0 width="95%"><TBODY><TR bgColor=#e1e1e1><TD><TABLE cellSpacing=2 cellPadding=2><TBODY><TR bgColor=#e1e1e1><TD vAlign=top align=middle bgColor=#ffffff>
View larger version (39K):
<NOBR>[in this window]
[in a new window]
</NOBR> </TD><TD vAlign=top align=left>Fig. 4. PKC
is required for Stat6 nuclear translocation. Th2 polarized WT or PKC
<SUP>?/?</SUP> (KO) cells were restimulated or left unstimulated with anti-CD3 or anti-CD3 plus anti-CD28 in the absence (a) or presence (b) of IL-4, and nuclear translocation of Stat6 was determined by confocal analysis. Stat6 (green) or TO-PRO nuclear (blue) staining was visualized. The results are representative of three independent experiments.
</TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></CENTER><SUP></SUP>
<!-- null -->
<CENTER><TABLE cellSpacing=0 cellPadding=0 width="95%"><TBODY><TR bgColor=#e1e1e1><TD><TABLE cellSpacing=2 cellPadding=2><TBODY><TR bgColor=#e1e1e1><TD vAlign=top align=middle bgColor=#ffffff>
View larger version (38K):
<NOBR>[in this window]
[in a new window]
</NOBR> </TD><TD vAlign=top align=left>Fig. 5. Role of PKC
in OVA-induced allergic airway disease. (a?d) OVA-induced allergic airway inflammation is impaired in PKC
<SUP>?/?</SUP> mice. Total cell numbers and eosinophils in BAL fluids were determined (a). Lung sections were prepared and stained with H&E (b) or with anti-CD11b (c). Levels of IL-4, IL-5, IL-13, and eotaxin in the BAL fluids were measured by ELISA (d). (e) Adoptively transferred Th2 WT into PKC
<SUP>?/?</SUP> (KO) cells can generate airway inflammation. Th2 WT and PKC
<SUP>?/?</SUP> (KO) cells were generated by using mice sensitized with OVA and alum. Th2 cells were collected and injected into either WT or PKC
<SUP>?/?</SUP> (KO) recipient mice. The mice were exposed to aerosolized OVA, and lungs were prepared for histology and stained with H&E. Data shown are representative of two experiments that each time involved six WT and six PKC
<SUP>?/?</SUP> (KO) mice. a and d are the mean ? SD; n = 6 for each genotype. **, P < 0.01; ***, P < 0.001.
</TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></CENTER>Adoptive Transfer Experiments Support a Critical Role of PKC
<SUP> </SUP>in Th2 Function. The results from the asthma model experiments<SUP> </SUP>are consistent with a critical role of PKC
in Th2 function.<SUP> </SUP>However, it would be of great interest to determine whether<SUP> </SUP>this phenotype is mostly due to defects in Th2 cells or whether<SUP> </SUP>the loss of PKC
in the lung resident cells might contribute<SUP> </SUP>to the inhibition in allergic airway inflammation observed in<SUP> </SUP>the PKC
mutant mice. To address this question, we transferred<SUP> </SUP>in vitro-generated WT and PKC
<SUP>?/?</SUP> Th2 cells into<SUP> </SUP>PKC
<SUP>?/?</SUP> mice and determined the sensitivity of these<SUP> </SUP>mice to the asthma model. Following a previously established<SUP> </SUP>method (16), we induced Th2 cells by i.p. injections of WT and<SUP> </SUP>PKC
<SUP>?/?</SUP> mice with OVA, and, after 5 days of immunization,<SUP> </SUP>CD4<SUP>+</SUP> T cells from spleens and lymph nodes were isolated and<SUP> </SUP>subsequently cultured with antigen-presenting cells, OVA, and<SUP> </SUP>IL-4 for 4 days. Afterward, Th2-polarized cells were i.v. injected<SUP> </SUP>in equal numbers into WT and PKC
<SUP>?/?</SUP> mice, whereas<SUP> </SUP>some control WT and PKC
<SUP>?/?</SUP> mice did not receive<SUP> </SUP>cells. Mice were then challenged with inhaled OVA as described<SUP> </SUP>in Materials and Methods. Twenty-four hours after the final<SUP> </SUP>challenge, mice were killed, and lung inflammation was analyzed<SUP> </SUP>histologically by H&E staining as above. Importantly, H&E<SUP> </SUP>histological analysis of lung sections from this experiment<SUP> </SUP>shows that whereas the challenged PKC
<SUP>?/?</SUP> mice that<SUP> </SUP>have been injected with PKC
<SUP>?/?</SUP> Th2 cells showed<SUP> </SUP>little or no inflammation, the mutant mice injected with WT<SUP> </SUP>Th2 cells displayed a prominent inflammatory response with massive<SUP> </SUP>perivascular and peribronchial infiltration (Fig. 5e). In contrast,<SUP> </SUP>the WT control mice that were not challenged showed no inflammation<SUP> </SUP>at all (Fig. 5e). Also, the injection of PKC
<SUP>?/?</SUP><SUP> </SUP>Th2 cells into WT mice did not produce significant inflammation<SUP> </SUP>(Fig. 5e). These results suggest that the loss of PKC
in the<SUP> </SUP>lung resident cells does not contribute in a significant manner<SUP> </SUP>to the OVA-induced airway inflammatory response and demonstrate<SUP> </SUP>the critical role of PKC
in Th2 function in vivo.<SUP> </SUP>
<!-- null -->
<TABLE cellSpacing=0 cellPadding=0 width="100%" bgColor=#e1e1e1><TBODY><TR><TD vAlign=center align=left width="5%" bgColor=#ffffff>
</TD><TH vAlign=center align=left width="95%"> Discussion </TH></TR></TBODY></TABLE><TABLE cellPadding=5 align=right border=1><TBODY><TR><TH align=left>
Top
Abstract
Materials and Methods
Results
Discussion
References
</TH></TR></TBODY></TABLE>
The understanding of the signaling cascades that regulate asthma,<SUP> </SUP>and Th2 polarization in particular, is an important issue in<SUP> </SUP>immunology. Because Th2 cells are critical players in the orchestration<SUP> </SUP>of the networks activated during allergic airway inflammation,<SUP> </SUP>these signaling pathways are a rich source of therapeutic targets<SUP> </SUP>in asthma and possibly other allergic diseases. The fact that<SUP> </SUP>PKC
is a critical modulator of the Th2 response strongly suggests<SUP> </SUP>that it is a potentially relevant target for these pathological<SUP> </SUP>alterations of the immune system. Our data indicate that the<SUP> </SUP>loss of PKC
leads to a clear impairment in the secretion of<SUP> </SUP>Th2 cytokines in ex vivo and in vivo experiments due to the<SUP> </SUP>inability of the PKC
<SUP>?/?</SUP> CD4<SUP>+</SUP> T cells to differentiate<SUP> </SUP>adequately along the Th2 lineage. Thus, the loss of PKC
results<SUP> </SUP>in the generation of Th2 cells in ex vivo cultures that poorly<SUP> </SUP>activate GATA3, c-Maf, Stat6, and NFATc1 during the Th2 differentiation<SUP> </SUP>program. Also, RelA activation is impaired in the PKC
<SUP>?/?</SUP><SUP> </SUP>cells. Although PKC
has been shown to be involved in NF-
B nuclear<SUP> </SUP>translocation and I
B kinase activation in lung (7) and liver<SUP> </SUP>(17), we think that the defect observed in RelA activation,<SUP> </SUP>and in the other transcription factors, in Th2-polarized cells<SUP> </SUP>is secondary to an impaired differentiation program in the mutant<SUP> </SUP>cells due to the essential role played by PKC
in IL-4 signaling.<SUP> </SUP>In this regard, Th2 differentiation in vitro is triggered by<SUP> </SUP>TCR activation and the IL-4 present in the culture medium. Notably,<SUP> </SUP>the activation of PKC
in anti-CD3-rechallenged Th2 cells requires<SUP> </SUP>the autocrinely secreted IL-4, suggesting that PKC
is not a<SUP> </SUP>direct downstream target of the TCR pathway but is a critical<SUP> </SUP>mediator of IL-4 signal transduction. Consistent with this model,<SUP> </SUP>IL-4 is sufficient to activate PKC
in na?ve T cells, and<SUP> </SUP>the loss of this kinase impairs Jak1/Stat6 activation by IL-4<SUP> </SUP>in these cells, whereas it is dispensable for the activation<SUP> </SUP>of TCR proximal signals such as ERK and NF-
B activation. Therefore,<SUP> </SUP>the results presented here establish PKC
as a critical player<SUP> </SUP>in the Th2 differentiation programs downstream the IL-4 receptor<SUP> </SUP>and independently from TCR-activated signals. The data are consistent<SUP> </SUP>with our previously published results that demonstrated that<SUP> </SUP>PKC
is not involved in TCR-driven activation of na?ve T<SUP> </SUP>cell proliferation and IL-2 production (8). Interestingly, the<SUP> </SUP>loss of PKC
leads to impaired Stat6 tyrosine phosphorylation<SUP> </SUP>and nuclear translocation due to the fact that PKC
is required<SUP> </SUP>for the proper stimulation of Jak1. Our previous results indicated<SUP> </SUP>that PKC
interacts with and phosphorylates Jak1 in vitro and<SUP> </SUP>in IL-4 activated cells (17), which offers a mechanistic explanation<SUP> </SUP>to the Th2 inflammatory phenotype of the PKC
mutant mice reported<SUP> </SUP>here.<SUP> </SUP>
Particularly relevant from the point of view of lung inflammatory<SUP> </SUP>pathologies are our results from the OVA-induced allergic airway<SUP> </SUP>disease model. These data validate PKC
in asthma, because the<SUP> </SUP>mutant mice show a dramatically reduced response to OVA-induced<SUP> </SUP>airway inflammation. This response is the consequence of a complex<SUP> </SUP>set of cellular interactions involving the recruited Th2 lymphocytes<SUP> </SUP>and lung resident cells (1, 11). Of note, adoptive transfer<SUP> </SUP>experiments reported in this study demonstrate that the loss<SUP> </SUP>of PKC
in lung resident cells does not contribute significantly<SUP> </SUP>to the impairment of the inflammatory response in this system,<SUP> </SUP>whereas the loss of PKC
in Th2 cells is of great importance.<SUP> </SUP>These data reinforce the notion that PKC
is required for Th2<SUP> </SUP>function due to its critical role in IL-4 signaling. Our results<SUP> </SUP>also explain previous observations that PKC
<SUP>?/?</SUP> mice<SUP> </SUP>have defects in mounting an optimal adaptive immune response<SUP> </SUP>to a T-dependent antigen without a defect in na?ve T cell<SUP> </SUP>activation (8). Thus, our system is different from the PKC
<SUP>?/?</SUP><SUP> </SUP>mice. In contrast to the PKC
<SUP>?/?</SUP> mice, which have<SUP> </SUP>a defect in Th2 cells but not in na?ve T cell proliferation<SUP> </SUP>(8), in the case of the PKC
<SUP>?/?</SUP> mice, the alterations<SUP> </SUP>were not restricted to the Th2 differentiation program (18?20);<SUP> </SUP>defects were also found in NF-
B activation and proliferation<SUP> </SUP>of na?ve T cells (21, 22), suggesting that the role of<SUP> </SUP>PKC
is more constrained to the Th2 polarization mechanism and<SUP> </SUP>that the role of PKC
has a broader impact in T cell function.<SUP> </SUP>
<!-- null -->
<TABLE cellSpacing=0 cellPadding=0 width="100%" bgColor=#e1e1e1><TBODY><TR><TD vAlign=center align=left width="5%" bgColor=#ffffff>
</TD><TH vAlign=center align=left width="95%"> Acknowledgements </TH></TR></TBODY></TABLE>
This work was supported by Ministerio de Ciencia y Tecnolog?a<SUP> </SUP>Grants SAF2003-02613 (to M.T.D.-M.) and SAF2002-0187 (to J.M.)<SUP> </SUP>and by an institutional grant from Fundaci?n Ram?n<SUP> </SUP>Areces to the Centro de Biolog?a Molecular Severo Ochoa.<SUP> </SUP>J.M. is recipient of the Ayuda Investigaci?n Juan March<SUP> </SUP>2001, and P.M. is the recipient of Consejo Superior de Investigaciones<SUP> </SUP>Cientificas Grant I3P-PC2003.<SUP> </SUP>
<!-- null -->
<TABLE cellSpacing=0 cellPadding=0 width="100%" bgColor=#e1e1e1><TBODY><TR><TD vAlign=center align=left width="5%" bgColor=#ffffff>
</TD><TH vAlign=center align=left width="95%"> Footnotes </TH></TR></TBODY></TABLE>
<!-- null -->Author contributions: P.M., P.R., G.M., C.M.-A, M.T.D.-M., and<SUP> </SUP>J.M. designed research; P.M., R.V., S.R.-M., A.Z., I.S., P.R.,<SUP> </SUP>and M.T.D.-M. performed research; M.L. and J.K. contributed<SUP> </SUP>new reagents/analytic tools; J.M. analyzed data; and G.M., M.T.D.-M.,<SUP> </SUP>and J.M. wrote the paper.<SUP> </SUP>
<!-- null -->This paper was submitted directly (Track II) to the PNAS office.<SUP> </SUP>
<!-- null -->Abbreviations: Th, T helper; OVA, ovalbumin; BAL, bronchoalveolar<SUP> </SUP>lavage; ERK, extracellular signal-regulated kinase; NFAT, nuclear<SUP> </SUP>factor of activated T cells; TCR, T cell receptor; H&E,<SUP> </SUP>hematoxylin/eosin.<SUP> </SUP>
<!-- null --><SUP>?</SUP> To whom correspondence should be addressed. E-mail: jmoscat@cbm.uam.es<SCRIPT type=text/javascript><!-- var u = "jmoscat", d = "cbm.uam.es"; document.getElementById("em0").innerHTML = '<a href="mailto:' + u + '@' + d + '">' + u + '@' + d + '<\/a>'//--></SCRIPT> .
? 2005 by The National Academy of Sciences of the USA
<!-- null -->
<TABLE cellSpacing=0 cellPadding=0 width="100%" bgColor=#e1e1e1><TBODY><TR><TD vAlign=center align=left width="5%" bgColor=#ffffff>
</TD><TH vAlign=center align=left width="95%"> References </TH></TR></TBODY></TABLE><TABLE cellPadding=5 align=right border=1><TBODY><TR><TH align=left>
Top
Abstract
Materials and Methods
Results
Discussion
References
</TH></TR></TBODY></TABLE>
</NOBR><NOBR>Pilar Martin<SUP> *</SUP></NOBR>, <NOBR>Ricardo Villares<SUP>
</SUP></NOBR>, <NOBR>Sandra Rodriguez-Mascarenhas<SUP> *</SUP></NOBR>, <NOBR>Angel Zaballos<SUP>
</SUP></NOBR>, <NOBR>Michael Leitges<SUP>
</SUP></NOBR>, <NOBR>Judit Kovac<SUP>
</SUP></NOBR>, <NOBR>Irene Sizing<SUP>
</SUP></NOBR>, <NOBR>Paul Rennert<SUP>
</SUP></NOBR>, <NOBR>Gabriel M?rquez<SUP>
</SUP></NOBR>, <NOBR>Carlos Mart?nez-A<SUP>
</SUP></NOBR>, <NOBR>Mar?a T. Diaz-Meco<SUP> *</SUP></NOBR>, and <NOBR>Jorge Moscat<SUP> *,</SUP><SUP> ?</SUP></NOBR> <SUP>*</SUP>Centro de Biolog?a Molecular Severo Ochoa and <SUP>
</SUP>Departamento de Inmunologia y Oncologia-Centro Nacional de Biotecnolog?a, Consejo Superior de Investigaciones Cientificas, Universidad Autonoma de Madrid, Cantoblanco, 28049 Madrid, Spain; <SUP>
</SUP>Max-Planck-Institut f?r Experimentelle Endokrinologie, Feodor-Lynen-Strasse 7, 30625 Hannover, Germany; and <SUP>
</SUP>Biogen, 14 Cambridge Center, Cambridge, MA 02142 Edited by Tak Wah Mak, University of Toronto, Toronto, ON, Canada, and approved May 20, 2005 (received for review February 11, 2005)
<!-- null -->
<TABLE cellSpacing=0 cellPadding=0 width="100%" bgColor=#e1e1e1><TBODY><TR><TD vAlign=center align=left width="5%" bgColor=#ffffff>
</TH></TR></TBODY></TABLE>
Asthma is a disease of chronic airway inflammation in which<SUP> </SUP>T helper (Th) 2 cells play a critical role. The molecular mechanisms<SUP> </SUP>controlling Th2 differentiation and function are of paramount<SUP> </SUP>importance in biology and immunology. PKC
has been implicated<SUP> </SUP>in the regulation of apoptosis and NF-
B, as well as in the control<SUP> </SUP>of T-dependent responses, although no defects were detected<SUP> </SUP>in na?ve T cells from PKC
<SUP>?/?</SUP> mice. Here, we<SUP> </SUP>report that PKC
is critical for IL-4 signaling and Th2 differentiation.<SUP> </SUP>Thus, PKC
levels are increased during Th2 differentiation, but<SUP> </SUP>not Th1 differentiation, of CD4<SUP>+</SUP> T cells, and the loss of PKC
<SUP> </SUP>impairs the secretion of Th2 cytokines in vitro and in vivo,<SUP> </SUP>as well as the nuclear translocation and tyrosine phosphorylation<SUP> </SUP>of Stat6 and Jak1 activation, essential downstream targets of<SUP> </SUP>IL-4 signaling. Moreover, PKC
<SUP>?/?</SUP> mice display dramatic<SUP> </SUP>inhibition of ovalbumin-induced allergic airway disease, strongly<SUP> </SUP>suggesting that PKC
can be a therapeutic target in asthma.<SUP> </SUP>apoptosis | asthma | NF-
B <HR align=center width="50%" noShade SIZE=1>Asthma is a chronic lung inflammatory disease with increased<SUP> </SUP>prevalence in developed countries. The pathology of asthma is<SUP> </SUP>associated with aberrant activation of CD4<SUP>+</SUP> lymphocytes differentiated<SUP> </SUP>along the T helper (Th) 2 lineage (1). Na?ve CD4<SUP>+</SUP> Th cells<SUP> </SUP>can differentiate in response to antigen stimulation into two<SUP> </SUP>distinct subsets of effector cells, Th1 and Th2, which display<SUP> </SUP>distinct cytokine profiles and immune regulatory functions (2).<SUP> </SUP>Th1 cells mainly produce IFN-
and IL-2 and are essential for<SUP> </SUP>cell-mediated immune responses against intracellular pathogens.<SUP> </SUP>Th2 cells produce a different set of cytokines, including IL-4,<SUP> </SUP>IL-5, IL-10, and IL-13, and are important in the control of<SUP> </SUP>humoral immunity and allergy (3). The signaling pathways controlling<SUP> </SUP>Th2 differentiation and function have been the focus of intense<SUP> </SUP>research because they could help to identify therapeutic targets<SUP> </SUP>for asthma and other allergic pathologies. IL-4 is important<SUP> </SUP>for induction and maintenance of differentiated Th2 cells and<SUP> </SUP>for B cell Ig isotype switching to IgE in mice (4). IL-4 and<SUP> </SUP>IL-13 share interactions with the IL-4R
chain and activate the<SUP> </SUP>transcription factor Stat6 through a Jak1/Jak3 signaling pathway<SUP> </SUP>(3, 5).<SUP> </SUP>The role of the different PKC isoforms in lymphocyte activation<SUP> </SUP>and differentiation is a matter of great interest. The recent<SUP> </SUP>generation of mutant mice in which different PKC isotypes have<SUP> </SUP>been genetically inactivated reveals the selective involvement<SUP> </SUP>of each PKC isoform in cell-specific aspects of the immune response<SUP> </SUP>(6). The characterization of knockout mice for the diacylglycerol-insensitive<SUP> </SUP>atypical PKC
isoform reveals an important role of this kinase<SUP> </SUP>in the immune system (7). Thus, PKC
<SUP>?/?</SUP> adult mice<SUP> </SUP>are unable to mount an optimal immune response (8), suggesting<SUP> </SUP>alterations in lymphocyte function. Although the humoral response<SUP> </SUP>to a T-independent antigen was reduced in the PKC
<SUP>?/?</SUP><SUP> </SUP>mice, the major defects were found in mice challenged with a<SUP> </SUP>T-dependent antigen, specifically, in the levels of IgG1, IgG2a,<SUP> </SUP>and IgG2b (8). Also, basal IgE levels were dramatically reduced<SUP> </SUP>in PKC
<SUP>?/?</SUP> mice compared with WT controls (8), indicating<SUP> </SUP>that some kind of T cell alteration, possibly in the Th2 lineage,<SUP> </SUP>might be produced by the loss of PKC
. Surprisingly, although<SUP> </SUP>the ability of B cells to proliferate in response to B cell<SUP> </SUP>receptor challenge was reproducibly impaired in the PKC
-deficient<SUP> </SUP>mice, no major alterations were observed in the proliferation<SUP> </SUP>of na?ve T cells (8). However, the potential role of PKC
<SUP> </SUP>in Th2 function and asthma had not been addressed previously.<SUP> </SUP><!-- null -->
<TABLE cellSpacing=0 cellPadding=0 width="100%" bgColor=#e1e1e1><TBODY><TR><TD vAlign=center align=left width="5%" bgColor=#ffffff>
</TH></TR></TBODY></TABLE>
Mice. PKC
<SUP>?/?</SUP> and WT mice (SV129J background) are<SUP> </SUP>described in ref. 7. Mice aged between 6 and 8 weeks were used<SUP> </SUP>for the in vitro experiments. Age- and sex-matched 10- to 12-week-old<SUP> </SUP>mice were used for the in vivo asthma model.<SUP> </SUP>Antibodies and Reagents. Antibodies to murine CD3
(145-2C11)<SUP> </SUP>and CD28 (37.51) and biotinylated CD8
(53-6.7), CD11b (Mac-1),<SUP> </SUP>CD16 (2.4G2), CD19 (1D3), CD24 (M1/69), CD62L (MEL-14), CD117<SUP> </SUP>(2B8), B220 (RA3-6B2), and CD4-FITC (L3T4) as well as IL-4-phycoerythrin<SUP> </SUP>(PE) and CD25-PE (PC61) were from Pharmingen. Antibodies to<SUP> </SUP>Stat6 (S-20), phospho-extracellular signal-regulated kinase<SUP> </SUP>(ERK) (E-4), ERK1 (K-23), phospholipase C-
(Y783), GATA3 (HG3?31),<SUP> </SUP>c-Maf (M-153), actin (I-19), T-bet (4B10), proliferating cell<SUP> </SUP>nuclear antigen (FL-261), and nuclear factor of activated T<SUP> </SUP>cells (NFAT) c1 (7A6) were from Santa Cruz Biotechnology. Stat5,<SUP> </SUP>Jak1, phospho-Stat6 (Tyr-641), phospho-Stat5 (Y694), and phospho-Jak1<SUP> </SUP>(Tyr-1022 and Tyr-1023) antibodies were from Cell Signaling<SUP> </SUP>Technology (Beverly, MA). Recombinant murine IL-2, IL-12, and<SUP> </SUP>IL-4 as well as anti-IFN-
, anti-IL-5, anti-IL-4R
, and anti-IL-4<SUP> </SUP>antibodies were from <!--ad-->R & D Systems. IFN-
, IL-4, IL-5, and<SUP> </SUP>IL-10 ELISA kits were from Pharmingen, and the IL-13 ELISA kit<SUP> </SUP>was from <!--ad-->R & D Systems. Specific polyclonal anti-PKC
antibody<SUP> </SUP>was generated against the sequence encompassing amino acids<SUP> </SUP>185?244 of PKC
.<SUP> </SUP>CD4<SUP>+</SUP> T Cell Isolation and Differentiation. To obtain na?ve<SUP> </SUP>CD4<SUP>+</SUP> T cells, single cell suspensions were prepared from spleens<SUP> </SUP>and mesenteric lymph nodes of the indicated mice and were incubated<SUP> </SUP>with biotinylated antibodies directed at CD8, CD16, CD19, CD24,<SUP> </SUP>CD117, major histocompatibility complex class II (I-A<SUP>b</SUP>), and<SUP> </SUP>CD11b followed by incubation with anti-biotin-conjugated microbeads.<SUP> </SUP>Na?ve CD4<SUP>+</SUP> T cells were negatively selected in an autoMACS<SUP> </SUP>separator (Miltenyi Biotec, Auburn, CA) according to the manufacturer's<SUP> </SUP>instructions. Purified CD4<SUP>+</SUP> T cells were labeled with antibodies<SUP> </SUP>specific for CD4, CD25, CD62L, and B220 and analyzed by flow<SUP> </SUP>cytometry to confirm purity and the na?ve status (Fig.<SUP> </SUP>6, which is published as supporting information on the PNAS<SUP> </SUP>web site). Na?ve CD4<SUP>+</SUP> T cells (10<SUP>6</SUP> cells per ml) were differentiated<SUP> </SUP>in the presence of irradiated antigen-presenting cells (10<SUP>6</SUP><SUP> </SUP>cells per ml), immobilized anti-CD3 (1 ?g/ml), and IL-2<SUP> </SUP>(10 ng/ml). For Th0 cultures, anti IL-4 (4 ?g/ml) and<SUP> </SUP>anti-IFN-
(4 ?g/ml) were added. For Th1 differentiation,<SUP> </SUP>IL-12 (3.5 ng/ml) and anti-IL-4 (4 ?g/ml) were added to<SUP> </SUP>the culture, whereas IL-4 (4 ng/ml) and anti-IFN-
(4 ?g/ml)<SUP> </SUP>were added for Th2 differentiation. After 4 days, the cells<SUP> </SUP>were extensively washed, counted, and restimulated as described.<SUP> </SUP>No differences in viability were observed in WT and knockout<SUP> </SUP>na?ve Th0, Th1, or Th2 cells.<SUP> </SUP>FACS Analysis and Intracellular Staining. GATA3 protein levels<SUP> </SUP>were assessed by intracellular staining in cells fixed overnight<SUP> </SUP>with 70% ethanol at ?20?C and stained with anti-GATA3<SUP> </SUP>or control mouse IgG1 followed by FITC-anti-mouse IgG1. To determine<SUP> </SUP>intracellular IL-4 levels, brefeldin A (BD GolgiPlug, BD Biosciences)<SUP> </SUP>was added 4 h before harvest to Th2 polarized WT and PKC
<SUP>?/?</SUP><SUP> </SUP>cells that had been restimulated for 48 h with anti-CD3 in the<SUP> </SUP>absence or presence of anti-CD28. Afterward, cells were fixed<SUP> </SUP>and permeabilized by using the BD Cytofix/Cytoperm kit (BD Biosciences)<SUP> </SUP>and stained with anti-IL-4-phycoerythrin. Analysis was performed<SUP> </SUP>in a FACSCalibur cell sorter (BD Biosciences) with CELLQUESTPRO<SUP> </SUP>software.<SUP> </SUP>PKC
Kinase Assay. Cell extracts prepared in lysis buffer (50<SUP> </SUP>mM Tris?HCl, pH 7.5/150 mM NaCl/1 mM EGTA/2 mM EDTA/1%<SUP> </SUP>Triton X-100) were immunoprecipitated with the specific anti-PKC
<SUP> </SUP>antibody that does not crossreact with PKC
/
for2hat4?C.<SUP> </SUP>Immunoprecipitates were captured with protein A and washed extensively<SUP> </SUP>in lysis buffer with 0.5 M NaCl. The enzymatic assay was carried<SUP> </SUP>out in the immunoprecipitates in assay buffer [35 mM Tris?HCl,<SUP> </SUP>pH 7.5/10 mM MgCl<SUB>2</SUB>/100 ?M CaCl<SUB>2</SUB>/0.5 mM EGTA/100 ?M<SUP> </SUP>ATP/5 ?Ci (1 Ci = 37 GBq) of [<SUP>32</SUP>P]ATP] with 4 ?g<SUP> </SUP>of myelin basic protein as substrate for 1 h at 30?C.<SUP> </SUP>Cytokine Assays. Na?ve CD4<SUP>+</SUP> T cells were stimulated for<SUP> </SUP>72 h with anti-CD3 (10 ?g/ml) plus anti-CD28 (5 ?g/ml),<SUP> </SUP>and Th2-differentiated cells were restimulated for 24 h with<SUP> </SUP>anti-CD3 (10 ?g/ml), after which, supernatants were collected<SUP> </SUP>and cytokine concentrations were measured by ELISA using commercially<SUP> </SUP>available kits. ELISA was also used to determine the levels<SUP> </SUP>of Th2 cytokines in bronchoalveolar lavage (BAL) fluids.<SUP> </SUP>
Immunofluorescent Analysis. Th2 cells (2 x 10<SUP>5</SUP>) were applied<SUP> </SUP>to glass slides by cytocentrifugation. Cells were fixed, permeabilized<SUP> </SUP>with 0.1% Triton X-100, and incubated with the different antibodies<SUP> </SUP>for 1 h at 37?C and the tetramethylfluorescein tyramide<SUP> </SUP>TSA-Direct amplification system (NEN). For the nuclear staining,<SUP> </SUP>cells were incubated with TO-PRO. Glass coverslips were mounted<SUP> </SUP>on Mowiol and examined with an MRC 1024 confocal system (Bio-Rad)<SUP> </SUP>mounted on an Axiovert 135 microscope (<!--ad-->Zeiss).<SUP> </SUP>
Ovalbumin (OVA)-Induced Allergic Airway Disease. PKC
<SUP>?/?</SUP><SUP> </SUP>and WT mice (10?12 weeks old) were immunized as described<SUP> </SUP>in ref. 9. Briefly, on day 0, 15 ?g of OVA (Sigma) in<SUP> </SUP>200 ?l of alum (Pierce) were injected i.p. into sensitized<SUP> </SUP>mice. On day 5, the animals received another i.p. injection<SUP> </SUP>of 15 ?g of OVA in 200 ?g of alum and, on day 12,<SUP> </SUP>mice were challenged with aerosolized 0.5% OVA in PBS (two challenges<SUP> </SUP>of 60 min each that were 4 h apart). Control animals were aerosolized<SUP> </SUP>with PBS. On day 14, 40 h after the second OVA challenge, mice<SUP> </SUP>were killed for analysis. For histological analysis, lungs from<SUP> </SUP>PBS- or OVA-treated mice were inflated through the trachea with<SUP> </SUP>50% Jung tissue-freezing medium (Leica, Vienna) in PBS. The<SUP> </SUP>right caudal lobe was trimmed, embedded, frozen, and stored<SUP> </SUP>at ?80?C. For the adoptive transfer experiments, WT<SUP> </SUP>and PKC
<SUP>?/?</SUP> mice were i.p. injected with 100 ?g<SUP> </SUP>of OVA in 2 mg of alum, and, 5 days later, spleens and mesenteric<SUP> </SUP>lymph nodes were removed for CD4<SUP>+</SUP> T cell isolation and were<SUP> </SUP>cultured for Th2 differentiation for 4 days with irradiated<SUP> </SUP>antigen-presenting cells, OVA (50 ?g/ml), IL-2 (10 ng/ml),<SUP> </SUP>IL-4 (10 ng/ml), and anti-IFN-
(10 ?g/ml). Afterward,<SUP> </SUP>Th2-like cells were collected, washed, and i.v. injected into<SUP> </SUP>WT and PKC
<SUP>?/?</SUP> recipient mice, which, 24 h later,<SUP> </SUP>were exposed to inhaled 1% OVA in PBS for a total of 7 days<SUP> </SUP>(4 consecutive days exposed, 2 days rested, and 3 consecutive<SUP> </SUP>days exposed) for 20 min daily. Mice were killed 24 h after<SUP> </SUP>the final exposure to antigen, and histological analysis of<SUP> </SUP>lungs was performed. The appropriate institutional animal use<SUP> </SUP>and care committees approved all animal experiments.<SUP> </SUP>Statistical Analysis. Statistical analyses were performed by<SUP> </SUP>using Student's t test. P < 0.05 was considered to be significant.<SUP> </SUP>
<!-- null -->
<TABLE cellSpacing=0 cellPadding=0 width="100%" bgColor=#e1e1e1><TBODY><TR><TD vAlign=center align=left width="5%" bgColor=#ffffff>
</TH></TR></TBODY></TABLE>
Impaired Th2 Differentiation in PKC
<SUP>?/?</SUP> Mice. To<SUP> </SUP>determine whether PKC
may play a role in lineage commitment<SUP> </SUP>of CD4<SUP>+</SUP> T helper cells, we initially differentiated CD4<SUP>+</SUP> T cells,<SUP> </SUP>either WT or PKC
<SUP>?/?</SUP>, in vitro under Th1 or Th2 polarizing<SUP> </SUP>conditions, after which, cells were stimulated with anti-CD3<SUP> </SUP>antibody for 48 h, and the secretion of IFN-
and IL-4 was determined<SUP> </SUP>in the Th1 and Th2 cultures, respectively. Results in Fig. 1a<SUP> </SUP>show that whereas IFN-
secretion is not affected, IL-4 is significantly<SUP> </SUP>reduced in PKC
<SUP>?/?</SUP> cells (Fig. 1a). The synthesis<SUP> </SUP>of three other Th2 cytokines, IL-5, IL-10, and IL-13, was also<SUP> </SUP>dramatically inhibited in PKC
<SUP>?/?</SUP> Th2 cells (Fig.<SUP> </SUP>1a). When the levels of intracellular IL-4 were determined in<SUP> </SUP>the presence of brefeldin A by FACS analysis, it was clear that<SUP> </SUP>WT Th2 cells produce significantly more IL-4 than do PKC
<SUP>?/?</SUP><SUP> </SUP>Th2 cells (Fig. 1b), consistent with the ELISA data in Fig.<SUP> </SUP>1a. Together, these results suggest that PKC
plays a nonredundant<SUP> </SUP>role in Th2-polarized CD4<SUP>+</SUP> T cells.<SUP> </SUP>GATA3 expression is a widely established hallmark of the Th2<SUP> </SUP>polarization process (10). Therefore, we initially analyzed<SUP> </SUP>by using flow cytometry the levels of this transcription factor<SUP> </SUP>in CD4<SUP>+</SUP> T cells incubated under Th0, Th1, and Th2 polarizing<SUP> </SUP>conditions. Interestingly, the loss of PKC
significantly reduces<SUP> </SUP>GATA3 expression in Th2 cells (Fig. 2a), strongly suggesting<SUP> </SUP>that PKC
plays an important role during Th2 differentiation.<SUP> </SUP>Consistent with this notion, the levels of GATA3, as well as<SUP> </SUP>the levels of Stat6, c-Maf, RelA, and NFATc1, were dramatically<SUP> </SUP>reduced in PKC
-deficient Th2 cells as determined by immunoblotting<SUP> </SUP>(Fig. 2b). Interestingly, when Th2-polarized T cells were rechallenged<SUP> </SUP>with anti-CD3 plus anti-CD28, the nuclear levels of all of the<SUP> </SUP>transcription factors tested were likewise inhibited in the<SUP> </SUP>PKC
<SUP>?/?</SUP> cells (Fig. 2c). Therefore, it seems that<SUP> </SUP>PKC
is required for the Th2 differentiation process to properly<SUP> </SUP>occur and for Th2-polarized cells to respond to an anti-CD3<SUP> </SUP>rechallenge.<SUP> </SUP>Signaling Cascades Inhibited in PKC
<SUP>?/?</SUP> T Cells Induced<SUP> </SUP>to Differentiate Along the Th2 Pathway. Because PKC
appears<SUP> </SUP>to be important for Th2 polarization, we next sought to determine<SUP> </SUP>whether this kinase is induced during this important differentiation<SUP> </SUP>process. First, we generated a polyclonal antibody that selectively<SUP> </SUP>recognizes PKC
and that does not crossreact with PKC
/
. The result<SUP> </SUP>in Fig. 3a shows the specificity of this antibody in immunoblot<SUP> </SUP>analysis of lung extracts, a tissue particularly rich in PKC
<SUP> </SUP>(7), from WT and PKC
<SUP>?/?</SUP> mice. Immunoblotting with<SUP> </SUP>an anti-PKC
/
-specific antibody of the same extracts reveals<SUP> </SUP>that the levels of this aPKC isoform were not affected by the<SUP> </SUP>loss of PKC
(Fig. 3a). Therefore, we next prepared extracts<SUP> </SUP>from CD4<SUP>+</SUP> T cells incubated under Th0, Th1, or Th2 conditions,<SUP> </SUP>and the expression of PKC
was determined by immunoblotting with<SUP> </SUP>our selective antibody. The data in Fig. 3b demonstrate that<SUP> </SUP>PKC
levels are increased under Th2 polarizing conditions, but<SUP> </SUP>not under Th1 polarizing conditions. Immunoblotting with anti-GATA3<SUP> </SUP>and anti-T-bet demonstrated that cells were properly polarized<SUP> </SUP>to the Th2 and Th1 lineages, respectively (Fig. 3b). To determine<SUP> </SUP>whether this induced PKC
is enzymatically active, we immunoprecipitated<SUP> </SUP>this kinase from polarized CD4<SUP>+</SUP> T cell extracts, and the enzymatic<SUP> </SUP>activity was determined in a standard kinase assay. The data<SUP> </SUP>in Fig. 3b show that the activity of PKC
is pronouncedly induced<SUP> </SUP>in Th2 cells.<SUP> </SUP><SUP></SUP>
<!-- null -->
<CENTER><TABLE cellSpacing=0 cellPadding=0 width="95%"><TBODY><TR bgColor=#e1e1e1><TD><TABLE cellSpacing=2 cellPadding=2><TBODY><TR bgColor=#e1e1e1><TD vAlign=top align=middle bgColor=#ffffff>

View larger version (24K):
<NOBR>[in this window]
[in a new window]
</NOBR> </TD><TD vAlign=top align=left>Fig. 1. Role of PKC
in Th2 differentiation and cytokine synthesis. (a) Secretion of IFN-
in Th1 cells or IL-5, IL-4, IL-13, and IL-10 in Th2 cells in WT or PKC
<SUP>?/?</SUP> (KO) mice stimulated with anti-CD3 was determined by ELISA. (b) IL-4 intracellular staining of Th2 cells in WT or PKC
<SUP>?/?</SUP> (KO) mice either untreated or treated with anti-CD3 alone or in combination with anti-CD28. Inset numbers represent the percentage of IL-4-positive cells. The results in a are the mean ? SD of three independent experiments with incubations in triplicate. The results in b are representative of another two experiments. ***, P < 0.001. </TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></CENTER><SUP></SUP>
<!-- null -->
<CENTER><TABLE cellSpacing=0 cellPadding=0 width="95%"><TBODY><TR bgColor=#e1e1e1><TD><TABLE cellSpacing=2 cellPadding=2><TBODY><TR bgColor=#e1e1e1><TD vAlign=top align=middle bgColor=#ffffff>

View larger version (40K):
<NOBR>[in this window]
[in a new window]
</NOBR> </TD><TD vAlign=top align=left>Fig. 2. Th2 transcription factors in PKC
<SUP>?/?</SUP> cells. (a) Intracellular staining of GATA3 in Th0, Th1, and Th2 cells in WT or PKC
<SUP>?/?</SUP> (KO) mice. The solid line represents GATA3 staining; the dashed line corresponds to the mouse IgG1 isotype control. Inset numbers represent the percentage of GATA3-positive cells. (b and c) Western blot analysis of nuclear levels of GATA3, Stat6, RelA, c-Maf, and NFATc1 in cell cultures as above (b) or in Th2 cells stimulated with anti-CD3 plus anti-CD28 (c). Anti-proliferating cell nuclear antigen was used as a loading control in b and c. The results are representative of three independent experiments. </TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></CENTER>Based on these observations and the impairment of Th2 differentiation<SUP> </SUP>and function of PKC
<SUP>?/?</SUP> T cells, we considered it<SUP> </SUP>important to determine whether PKC
is activated in Th2 cells<SUP> </SUP>upon T cell receptor (TCR) activation. Thus, CD4<SUP>+</SUP> T cells polarized<SUP> </SUP>under Th2 conditions were incubated with anti-CD3, and, afterward,<SUP> </SUP>PKC
enzymatic activity was determined as above. The incubation<SUP> </SUP>with anti-CD3 triggers a dramatic increase in PKC
activity (Fig.<SUP> </SUP>3c) without appreciable changes in the levels of the enzyme<SUP> </SUP>(Fig. 3c). Collectively, these results indicate that PKC
is<SUP> </SUP>activated when Th2-polarized CD4<SUP>+</SUP> T cells are rechallenged with<SUP> </SUP>anti-CD3. Th differentiation is modulated by signals emanating<SUP> </SUP>from the TCR and the cytokines generated during this polarization<SUP> </SUP>process, particularly IL-4, which is present in the culture<SUP> </SUP>medium of CD4<SUP>+</SUP> T cells induced to differentiate to the Th2 lineage.<SUP> </SUP>Importantly, IL-4 is synthesized by Th2 cells when rechallenged<SUP> </SUP>with an anti-CD3 antibody in the absence of any exogenous cytokine,<SUP> </SUP>which exerts a positive feedback activation loop (11). To determine<SUP> </SUP>whether PKC
activation in CD3-triggered CD4<SUP>+</SUP> T cells polarized<SUP> </SUP>under Th2 conditions is a direct effect of TCR signaling or<SUP> </SUP>whether it is mediated by the secreted IL-4, WT CD4<SUP>+</SUP> Th2 cells<SUP> </SUP>activated with anti-CD3 were incubated in the presence of either<SUP> </SUP>neutralizing anti-IL-4 or anti-IL-5 antibodies, after which,<SUP> </SUP>PKC
activity was determined as above. According to the results<SUP> </SUP>of Fig. 3c, PKC
activation by anti-CD3 is dramatically inhibited<SUP> </SUP>by the presence of anti-IL-4 but not by the presence of anti-IL-5<SUP> </SUP>(Fig. 3c). These results indicate that IL-4 is responsible for<SUP> </SUP>the activation of PKC
in CD3-restimulated Th2 cells and that<SUP> </SUP>PKC
could be part of the IL-4 signaling machinery but that it<SUP> </SUP>is not a direct step in the TCR signal transduction cascade.<SUP> </SUP>To address this point, na?ve CD4<SUP>+</SUP> T cells were incubated<SUP> </SUP>with IL-4 for different times, and PKC
enzymatic activity was<SUP> </SUP>determined as above. Interestingly, the addition of IL-4 provokes<SUP> </SUP>a reproducible and robust activation of PKC
in these cells (Fig.<SUP> </SUP>3d), demonstrating that PKC
constitutes a potentially important<SUP> </SUP>step in IL-4 signaling. If this model is correct, that would<SUP> </SUP>imply that the activation of signaling cascades of the TCR should<SUP> </SUP>not be impaired in the PKC
<SUP>?/?</SUP> na?ve CD4<SUP>+</SUP> T<SUP> </SUP>cells but that the stimulation of the IL-4 pathway should be<SUP> </SUP>inhibited. To address this point, we incubated na?ve WT<SUP> </SUP>and PKC
<SUP>?/?</SUP> CD4<SUP>+</SUP> T cells with or without IL-4, after<SUP> </SUP>which, tyrosine phosphorylation of Stat6 and Jak1 was determined<SUP> </SUP>by immunoblotting with phospho-site-specific antibodies. Results<SUP> </SUP>in Fig. 3e Left demonstrate that the loss of PKC
dramatically<SUP> </SUP>impairs the activation of Stat6 and Jak1 in na?ve CD4<SUP>+</SUP><SUP> </SUP>T cells. However, the loss of PKC
does not affect the activation<SUP> </SUP>of ERK or NFATc1 (Fig. 3f) or that of NF-
B (Fig. 3g) or I
B kinase<SUP> </SUP>activity (Fig. 3h) in these cells when stimulated with anti-CD3<SUP> </SUP>plus anti-CD28. The secretion of IL-4 and IL-5 in na?ve<SUP> </SUP>CD4<SUP>+</SUP> T cells activated with anti-CD3 is normal in the PKC
<SUP>?/?</SUP><SUP> </SUP>cells (Fig. 3i), reinforcing the notion that PKC
is not a direct<SUP> </SUP>target of TCR signaling. Likewise, the loss of PKC
did not affect<SUP> </SUP>IL-2-induced Stat5 activation in this system (Fig. 3e Right).<SUP> </SUP>Taken together, these results suggest that the defect in Th2-polarized<SUP> </SUP>cells is accounted for by the important role played by PKC
in<SUP> </SUP>IL-4 signaling but not in TCR downstream events. This model<SUP> </SUP>is consistent with our previously published results that demonstrated<SUP> </SUP>the lack of defects in the proliferation of na?ve T cells<SUP> </SUP>from PKC
<SUP>?/?</SUP> mice, a phenomenon that is clearly dependent<SUP> </SUP>on IL-2 production and signaling (8). In contrast, because the<SUP> </SUP>common
-chain receptor is essential for IL-2 and IL-4 function,<SUP> </SUP>the fact that IL-2 signaling is intact in the PKC
<SUP>?/?</SUP><SUP> </SUP>mice (Fig. 3e Right) indicates that the defects observed in<SUP> </SUP>the IL-4 pathway cannot be explained by potential alterations<SUP> </SUP>in the levels of this receptor subunit. In addition, the data<SUP> </SUP>in Fig. 7, which is published as supporting information on the<SUP> </SUP>PNAS web site, demonstrate that the levels of the
-chain of<SUP> </SUP>the IL-4 receptor are intact in na?ve and Th2-polarized<SUP> </SUP>T cells as demonstrated by FACS analysis to detect surface expression<SUP> </SUP>of the receptor (Fig. 1a) and immunoblotting (Fig. 1b). Interestingly,<SUP> </SUP>the nuclear translocation of activated Stat6 is dramatically<SUP> </SUP>inhibited in the PKC
<SUP>?/?</SUP> Th2 cells (Fig. 4a), and<SUP> </SUP>the exogenous addition of IL-4 does not bypass this blockade<SUP> </SUP>(Fig. 4b). These results are consistent with the notion that<SUP> </SUP>PKC
is required for the efficient activation of Jak1 and the<SUP> </SUP>subsequent phosphorylation and nuclear translocation of Stat6.<SUP> </SUP><SUP></SUP>
<!-- null -->
<CENTER><TABLE cellSpacing=0 cellPadding=0 width="95%"><TBODY><TR bgColor=#e1e1e1><TD><TABLE cellSpacing=2 cellPadding=2><TBODY><TR bgColor=#e1e1e1><TD vAlign=top align=middle bgColor=#ffffff>

View larger version (35K):
<NOBR>[in this window]
[in a new window]
</NOBR> </TD><TD vAlign=top align=left>Fig. 3. Biochemical signaling pathways in PKC
<SUP>?/?</SUP> cells. (a) Western blot analysis of PKC
and PKC
/
in lung from WT and PKC
<SUP>?/?</SUP> (KO) mice. (b) Extracts from CD4<SUP>+</SUP> T cells incubated under Th0, Th1, or Th2 polarizing conditions were analyzed by immunoblotting for PKC
, GATA3, and T-bet expression and by PKC
kinase activity (KA). (c) WT Th2-polarized T cells were incubated with or without anti-CD3 in the presence or absence of neutralizing anti-IL-4 or anti-IL-5 antibodies, and PKC
kinase activity (KA) and PKC
levels were determined. (d) PKC
kinase activity (KA) and PKC
levels were measured in Th2-polarized cells stimulated with IL-4 for different times. (e) Na?ve CD4<SUP>+</SUP> T cells were stimulated or not stimulated with IL-4 or IL-2 for 10 min; afterward, phospho-Stat6, phospho-Jak1, and phospho-Stat5 levels, as well as levels of Stat6, Jak1, and Stat5, were determined by immunoblotting. (f) Western blot analysis of phospho-ERK, ERK, and NFATc1 in na?ve CD4<SUP>+</SUP> T cells stimulated with anti-CD3 plus anti-CD28. (g) NF-
B activation was analyzed by EMSA in nuclear extracts prepared from na?ve CD4<SUP>+</SUP> T cells stimulated with anti-CD3 plus anti-CD28. (h) I
B kinase activity was determined in the above extracts. The results are representative of three independent experiments. (i) Cytokine production of IL-4 and IL-5 analyzed by ELISA in na?ve CD4<SUP>+</SUP> T cells, either WT or PKC
<SUP>?/?</SUP> (KO), stimulated with anti-CD3 plus anti-CD28. The results are the mean ? SD of three independent experiments with incubations in triplicate. </TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></CENTER>Loss of PKC
Inhibits Allergic Airway Disease. It is well established<SUP> </SUP>that the Th2 immune response is responsible of the development<SUP> </SUP>of allergic airway inflammation (12?15). Because the loss<SUP> </SUP>of PKC
results in impaired Th2 activation, we reasoned that<SUP> </SUP>PKC
<SUP>?/?</SUP> mice would display reduced inflammatory response<SUP> </SUP>in a model of OVA-induced allergic airway disease that predominantly<SUP> </SUP>generates a Th2 response. Therefore, mice that are either WT<SUP> </SUP>or PKC
<SUP>?/?</SUP> were sensitized to OVA and then challenged<SUP> </SUP>twice with aerosolized antigen or PBS on the same day. Forty-eight<SUP> </SUP>hours after the aerosol challenge, mice were killed, the lungs<SUP> </SUP>were examined histologically by hematoxylin/eosin (H&E)<SUP> </SUP>staining for eosinophilic infiltration, and BAL was performed<SUP> </SUP>to determine inflammatory cell recruitment. There was a robust<SUP> </SUP>increase in total BAL cell numbers in WT mice that were OVA<SUP> </SUP>sensitized and challenged with aerosolized antigen compared<SUP> </SUP>with PBS-challenged mice (Fig. 5a Left), due especially to eosinophils<SUP> </SUP>(Fig. 5a Right). However, this increase was dramatically reduced<SUP> </SUP>in the PKC
<SUP>?/?</SUP> mice (Fig. 5a), indicating that the<SUP> </SUP>impairment in the Th2 response observed in these mutant mice<SUP> </SUP>inhibits airway inflammation. Consistent with this notion, H&E<SUP> </SUP>histological analysis of lung sections from this experiment<SUP> </SUP>shows that whereas the challenged WT mice display a prominent<SUP> </SUP>inflammatory response with massive perivascular and peribronchial<SUP> </SUP>infiltration with abundant eosinophils, PKC
<SUP>?/?</SUP> mice<SUP> </SUP>display a much more attenuated response (Fig. 5b). CD11b staining<SUP> </SUP>confirms a dramatic reduction in granulocyte infiltration in<SUP> </SUP>the OVA-challenged PKC
<SUP>?/?</SUP> mice (Fig. 5c). The production<SUP> </SUP>of mucus in asthmatic patients is severely debilitating and<SUP> </SUP>may lead to death. Periodic acid Schiff's base staining of lung<SUP> </SUP>sections consistently showed mucus production in the airway<SUP> </SUP>epithelium and alveoli of WT mice. In contrast, and concurring<SUP> </SUP>with the milder allergic response to the OVA challenge observed<SUP> </SUP>in the PKC
<SUP>?/?</SUP> mice, mucus production was not observed<SUP> </SUP>in lung sections from these animals (data not shown). In addition,<SUP> </SUP>BAL IL-4, IL-5, IL-13, and eotaxin (Fig. 5d) supernatant levels,<SUP> </SUP>which were dramatically increased in OVA-challenged WT mice,<SUP> </SUP>were severely reduced in similarly treated PKC
<SUP>?/?</SUP><SUP> </SUP>mice.<SUP> </SUP><SUP></SUP>
<!-- null -->
<CENTER><TABLE cellSpacing=0 cellPadding=0 width="95%"><TBODY><TR bgColor=#e1e1e1><TD><TABLE cellSpacing=2 cellPadding=2><TBODY><TR bgColor=#e1e1e1><TD vAlign=top align=middle bgColor=#ffffff>

View larger version (39K):
<NOBR>[in this window]
[in a new window]
</NOBR> </TD><TD vAlign=top align=left>Fig. 4. PKC
is required for Stat6 nuclear translocation. Th2 polarized WT or PKC
<SUP>?/?</SUP> (KO) cells were restimulated or left unstimulated with anti-CD3 or anti-CD3 plus anti-CD28 in the absence (a) or presence (b) of IL-4, and nuclear translocation of Stat6 was determined by confocal analysis. Stat6 (green) or TO-PRO nuclear (blue) staining was visualized. The results are representative of three independent experiments. </TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></CENTER><SUP></SUP>
<!-- null -->
<CENTER><TABLE cellSpacing=0 cellPadding=0 width="95%"><TBODY><TR bgColor=#e1e1e1><TD><TABLE cellSpacing=2 cellPadding=2><TBODY><TR bgColor=#e1e1e1><TD vAlign=top align=middle bgColor=#ffffff>

View larger version (38K):
<NOBR>[in this window]
[in a new window]
</NOBR> </TD><TD vAlign=top align=left>Fig. 5. Role of PKC
in OVA-induced allergic airway disease. (a?d) OVA-induced allergic airway inflammation is impaired in PKC
<SUP>?/?</SUP> mice. Total cell numbers and eosinophils in BAL fluids were determined (a). Lung sections were prepared and stained with H&E (b) or with anti-CD11b (c). Levels of IL-4, IL-5, IL-13, and eotaxin in the BAL fluids were measured by ELISA (d). (e) Adoptively transferred Th2 WT into PKC
<SUP>?/?</SUP> (KO) cells can generate airway inflammation. Th2 WT and PKC
<SUP>?/?</SUP> (KO) cells were generated by using mice sensitized with OVA and alum. Th2 cells were collected and injected into either WT or PKC
<SUP>?/?</SUP> (KO) recipient mice. The mice were exposed to aerosolized OVA, and lungs were prepared for histology and stained with H&E. Data shown are representative of two experiments that each time involved six WT and six PKC
<SUP>?/?</SUP> (KO) mice. a and d are the mean ? SD; n = 6 for each genotype. **, P < 0.01; ***, P < 0.001. </TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></CENTER>Adoptive Transfer Experiments Support a Critical Role of PKC
<SUP> </SUP>in Th2 Function. The results from the asthma model experiments<SUP> </SUP>are consistent with a critical role of PKC
in Th2 function.<SUP> </SUP>However, it would be of great interest to determine whether<SUP> </SUP>this phenotype is mostly due to defects in Th2 cells or whether<SUP> </SUP>the loss of PKC
in the lung resident cells might contribute<SUP> </SUP>to the inhibition in allergic airway inflammation observed in<SUP> </SUP>the PKC
mutant mice. To address this question, we transferred<SUP> </SUP>in vitro-generated WT and PKC
<SUP>?/?</SUP> Th2 cells into<SUP> </SUP>PKC
<SUP>?/?</SUP> mice and determined the sensitivity of these<SUP> </SUP>mice to the asthma model. Following a previously established<SUP> </SUP>method (16), we induced Th2 cells by i.p. injections of WT and<SUP> </SUP>PKC
<SUP>?/?</SUP> mice with OVA, and, after 5 days of immunization,<SUP> </SUP>CD4<SUP>+</SUP> T cells from spleens and lymph nodes were isolated and<SUP> </SUP>subsequently cultured with antigen-presenting cells, OVA, and<SUP> </SUP>IL-4 for 4 days. Afterward, Th2-polarized cells were i.v. injected<SUP> </SUP>in equal numbers into WT and PKC
<SUP>?/?</SUP> mice, whereas<SUP> </SUP>some control WT and PKC
<SUP>?/?</SUP> mice did not receive<SUP> </SUP>cells. Mice were then challenged with inhaled OVA as described<SUP> </SUP>in Materials and Methods. Twenty-four hours after the final<SUP> </SUP>challenge, mice were killed, and lung inflammation was analyzed<SUP> </SUP>histologically by H&E staining as above. Importantly, H&E<SUP> </SUP>histological analysis of lung sections from this experiment<SUP> </SUP>shows that whereas the challenged PKC
<SUP>?/?</SUP> mice that<SUP> </SUP>have been injected with PKC
<SUP>?/?</SUP> Th2 cells showed<SUP> </SUP>little or no inflammation, the mutant mice injected with WT<SUP> </SUP>Th2 cells displayed a prominent inflammatory response with massive<SUP> </SUP>perivascular and peribronchial infiltration (Fig. 5e). In contrast,<SUP> </SUP>the WT control mice that were not challenged showed no inflammation<SUP> </SUP>at all (Fig. 5e). Also, the injection of PKC
<SUP>?/?</SUP><SUP> </SUP>Th2 cells into WT mice did not produce significant inflammation<SUP> </SUP>(Fig. 5e). These results suggest that the loss of PKC
in the<SUP> </SUP>lung resident cells does not contribute in a significant manner<SUP> </SUP>to the OVA-induced airway inflammatory response and demonstrate<SUP> </SUP>the critical role of PKC
in Th2 function in vivo.<SUP> </SUP><!-- null -->
<TABLE cellSpacing=0 cellPadding=0 width="100%" bgColor=#e1e1e1><TBODY><TR><TD vAlign=center align=left width="5%" bgColor=#ffffff>
</TH></TR></TBODY></TABLE>
The understanding of the signaling cascades that regulate asthma,<SUP> </SUP>and Th2 polarization in particular, is an important issue in<SUP> </SUP>immunology. Because Th2 cells are critical players in the orchestration<SUP> </SUP>of the networks activated during allergic airway inflammation,<SUP> </SUP>these signaling pathways are a rich source of therapeutic targets<SUP> </SUP>in asthma and possibly other allergic diseases. The fact that<SUP> </SUP>PKC
is a critical modulator of the Th2 response strongly suggests<SUP> </SUP>that it is a potentially relevant target for these pathological<SUP> </SUP>alterations of the immune system. Our data indicate that the<SUP> </SUP>loss of PKC
leads to a clear impairment in the secretion of<SUP> </SUP>Th2 cytokines in ex vivo and in vivo experiments due to the<SUP> </SUP>inability of the PKC
<SUP>?/?</SUP> CD4<SUP>+</SUP> T cells to differentiate<SUP> </SUP>adequately along the Th2 lineage. Thus, the loss of PKC
results<SUP> </SUP>in the generation of Th2 cells in ex vivo cultures that poorly<SUP> </SUP>activate GATA3, c-Maf, Stat6, and NFATc1 during the Th2 differentiation<SUP> </SUP>program. Also, RelA activation is impaired in the PKC
<SUP>?/?</SUP><SUP> </SUP>cells. Although PKC
has been shown to be involved in NF-
B nuclear<SUP> </SUP>translocation and I
B kinase activation in lung (7) and liver<SUP> </SUP>(17), we think that the defect observed in RelA activation,<SUP> </SUP>and in the other transcription factors, in Th2-polarized cells<SUP> </SUP>is secondary to an impaired differentiation program in the mutant<SUP> </SUP>cells due to the essential role played by PKC
in IL-4 signaling.<SUP> </SUP>In this regard, Th2 differentiation in vitro is triggered by<SUP> </SUP>TCR activation and the IL-4 present in the culture medium. Notably,<SUP> </SUP>the activation of PKC
in anti-CD3-rechallenged Th2 cells requires<SUP> </SUP>the autocrinely secreted IL-4, suggesting that PKC
is not a<SUP> </SUP>direct downstream target of the TCR pathway but is a critical<SUP> </SUP>mediator of IL-4 signal transduction. Consistent with this model,<SUP> </SUP>IL-4 is sufficient to activate PKC
in na?ve T cells, and<SUP> </SUP>the loss of this kinase impairs Jak1/Stat6 activation by IL-4<SUP> </SUP>in these cells, whereas it is dispensable for the activation<SUP> </SUP>of TCR proximal signals such as ERK and NF-
B activation. Therefore,<SUP> </SUP>the results presented here establish PKC
as a critical player<SUP> </SUP>in the Th2 differentiation programs downstream the IL-4 receptor<SUP> </SUP>and independently from TCR-activated signals. The data are consistent<SUP> </SUP>with our previously published results that demonstrated that<SUP> </SUP>PKC
is not involved in TCR-driven activation of na?ve T<SUP> </SUP>cell proliferation and IL-2 production (8). Interestingly, the<SUP> </SUP>loss of PKC
leads to impaired Stat6 tyrosine phosphorylation<SUP> </SUP>and nuclear translocation due to the fact that PKC
is required<SUP> </SUP>for the proper stimulation of Jak1. Our previous results indicated<SUP> </SUP>that PKC
interacts with and phosphorylates Jak1 in vitro and<SUP> </SUP>in IL-4 activated cells (17), which offers a mechanistic explanation<SUP> </SUP>to the Th2 inflammatory phenotype of the PKC
mutant mice reported<SUP> </SUP>here.<SUP> </SUP>Particularly relevant from the point of view of lung inflammatory<SUP> </SUP>pathologies are our results from the OVA-induced allergic airway<SUP> </SUP>disease model. These data validate PKC
in asthma, because the<SUP> </SUP>mutant mice show a dramatically reduced response to OVA-induced<SUP> </SUP>airway inflammation. This response is the consequence of a complex<SUP> </SUP>set of cellular interactions involving the recruited Th2 lymphocytes<SUP> </SUP>and lung resident cells (1, 11). Of note, adoptive transfer<SUP> </SUP>experiments reported in this study demonstrate that the loss<SUP> </SUP>of PKC
in lung resident cells does not contribute significantly<SUP> </SUP>to the impairment of the inflammatory response in this system,<SUP> </SUP>whereas the loss of PKC
in Th2 cells is of great importance.<SUP> </SUP>These data reinforce the notion that PKC
is required for Th2<SUP> </SUP>function due to its critical role in IL-4 signaling. Our results<SUP> </SUP>also explain previous observations that PKC
<SUP>?/?</SUP> mice<SUP> </SUP>have defects in mounting an optimal adaptive immune response<SUP> </SUP>to a T-dependent antigen without a defect in na?ve T cell<SUP> </SUP>activation (8). Thus, our system is different from the PKC
<SUP>?/?</SUP><SUP> </SUP>mice. In contrast to the PKC
<SUP>?/?</SUP> mice, which have<SUP> </SUP>a defect in Th2 cells but not in na?ve T cell proliferation<SUP> </SUP>(8), in the case of the PKC
<SUP>?/?</SUP> mice, the alterations<SUP> </SUP>were not restricted to the Th2 differentiation program (18?20);<SUP> </SUP>defects were also found in NF-
B activation and proliferation<SUP> </SUP>of na?ve T cells (21, 22), suggesting that the role of<SUP> </SUP>PKC
is more constrained to the Th2 polarization mechanism and<SUP> </SUP>that the role of PKC
has a broader impact in T cell function.<SUP> </SUP><!-- null -->
<TABLE cellSpacing=0 cellPadding=0 width="100%" bgColor=#e1e1e1><TBODY><TR><TD vAlign=center align=left width="5%" bgColor=#ffffff>
This work was supported by Ministerio de Ciencia y Tecnolog?a<SUP> </SUP>Grants SAF2003-02613 (to M.T.D.-M.) and SAF2002-0187 (to J.M.)<SUP> </SUP>and by an institutional grant from Fundaci?n Ram?n<SUP> </SUP>Areces to the Centro de Biolog?a Molecular Severo Ochoa.<SUP> </SUP>J.M. is recipient of the Ayuda Investigaci?n Juan March<SUP> </SUP>2001, and P.M. is the recipient of Consejo Superior de Investigaciones<SUP> </SUP>Cientificas Grant I3P-PC2003.<SUP> </SUP>
<!-- null -->
<TABLE cellSpacing=0 cellPadding=0 width="100%" bgColor=#e1e1e1><TBODY><TR><TD vAlign=center align=left width="5%" bgColor=#ffffff>
<!-- null -->Author contributions: P.M., P.R., G.M., C.M.-A, M.T.D.-M., and<SUP> </SUP>J.M. designed research; P.M., R.V., S.R.-M., A.Z., I.S., P.R.,<SUP> </SUP>and M.T.D.-M. performed research; M.L. and J.K. contributed<SUP> </SUP>new reagents/analytic tools; J.M. analyzed data; and G.M., M.T.D.-M.,<SUP> </SUP>and J.M. wrote the paper.<SUP> </SUP>
<!-- null -->This paper was submitted directly (Track II) to the PNAS office.<SUP> </SUP>
<!-- null -->Abbreviations: Th, T helper; OVA, ovalbumin; BAL, bronchoalveolar<SUP> </SUP>lavage; ERK, extracellular signal-regulated kinase; NFAT, nuclear<SUP> </SUP>factor of activated T cells; TCR, T cell receptor; H&E,<SUP> </SUP>hematoxylin/eosin.<SUP> </SUP>
<!-- null --><SUP>?</SUP> To whom correspondence should be addressed. E-mail: jmoscat@cbm.uam.es<SCRIPT type=text/javascript><!-- var u = "jmoscat", d = "cbm.uam.es"; document.getElementById("em0").innerHTML = '<a href="mailto:' + u + '@' + d + '">' + u + '@' + d + '<\/a>'//--></SCRIPT> .
? 2005 by The National Academy of Sciences of the USA
<!-- null -->
<TABLE cellSpacing=0 cellPadding=0 width="100%" bgColor=#e1e1e1><TBODY><TR><TD vAlign=center align=left width="5%" bgColor=#ffffff>
</TH></TR></TBODY></TABLE>
- <!-- null --><LI value=1>Luster, A. D. & Tager, A. M. (2004) Nat. Rev. Immunol. 4, 711?724.<!-- HIGHWIRE ID="102:28:9866:1" -->[CrossRef][ISI][Medline] <!-- /HIGHWIRE --><!-- null --><LI value=2>Mosmann, T. R. & Coffman, R. L. (1989) Annu. Rev. Immunol. 7, 145?173.<!-- HIGHWIRE ID="102:28:9866:2" -->[CrossRef][ISI][Medline] <!-- /HIGHWIRE --><!-- null --><LI value=3>Shuai, K. & Liu, B. (2003) Nat. Rev. Immunol. 3, 900?911.<!-- HIGHWIRE ID="102:28:9866:3" -->[CrossRef][ISI][Medline] <!-- /HIGHWIRE --><!-- null --><LI value=4>Paul, W. E. & Seder, R. A. (1994) Cell 76, 241?251.<!-- HIGHWIRE ID="102:28:9866:4" -->[CrossRef][ISI][Medline] <!-- /HIGHWIRE --><!-- null --><LI value=5>O'Shea, J. J., Gadina, M. & Schreiber, R. D. (2002) Cell 109, Suppl., S121?S131.<!-- HIGHWIRE ID="102:28:9866:5" -->[CrossRef][ISI][Medline] <!-- /HIGHWIRE --><!-- null --><LI value=6>Moscat, J., Diaz-Meco, M. T. & Rennert, P. (2003) EMBO Rep. 4, 31?36.<!-- HIGHWIRE ID="102:28:9866:6" -->[CrossRef][ISI][Medline] <!-- /HIGHWIRE --><!-- null --><LI value=7>Leitges, M., Sanz, L., Martin, P., Duran, A., Braun, U., Garcia, J. F., Camacho, F., Diaz-Meco, M. T., Rennert, P. D. & Moscat, J. (2001) Mol. Cell 8, 771?780.<!-- HIGHWIRE ID="102:28:9866:7" -->[CrossRef][ISI][Medline] <!-- /HIGHWIRE --><!-- null --><LI value=8>Martin, P., Duran, A., Minguet, S., Gaspar, M. L., Diaz-Meco, M. T., Rennert, P., Leitges, M. & Moscat, J. (2002) EMBO J. 21, 4049?4057.<!-- HIGHWIRE ID="102:28:9866:8" -->[CrossRef][ISI][Medline] <!-- /HIGHWIRE --><!-- null --><LI value=9>Chensue, S. W., Lukacs, N. W., Yang, T. Y., Shang, X., Frait, K. A., Kunkel, S. L., Kung, T., Wiekowski, M. T., Hedrick, J. A., Cook, D. N., et al. (2001) J. Exp. Med. 193, 573?584.<!-- HIGHWIRE ID="102:28:9866:9" --><NOBR>[Abstract/Free Full Text]</NOBR><!-- /HIGHWIRE --><!-- null --> <LI value=10>Ho, I. C. & Glimcher, L. H. (2002) Cell 109, Suppl., S109?S120.<!-- HIGHWIRE ID="102:28:9866:10" -->[CrossRef][ISI][Medline] <!-- /HIGHWIRE --><!-- null --><LI value=11>Murphy, K. M. & Reiner, S. L. (2002) Nat. Rev. Immunol. 2, 933?944.<!-- HIGHWIRE ID="102:28:9866:11" -->[CrossRef][ISI][Medline] <!-- /HIGHWIRE --><!-- null --><LI value=12>Elias, J. A., Lee, C. G., Zheng, T., Ma, B., Homer, R. J. & Zhu, Z. (2003) J. Clin. Invest. 111, 291?297.<!-- HIGHWIRE ID="102:28:9866:12" --><NOBR>[Free Full Text]</NOBR><!-- /HIGHWIRE --><!-- null --> <LI value=13>Pernis, A. B. & Rothman, P. B. (2002) J. Clin. Invest. 109, 1279?1283.<!-- HIGHWIRE ID="102:28:9866:13" --><NOBR>[Free Full Text]</NOBR><!-- /HIGHWIRE --><!-- null --> <LI value=14>Ray, A. & Cohn, L. (1999) J. Clin. Invest. 104, 985?993.<!-- HIGHWIRE ID="102:28:9866:14" --><NOBR>[Free Full Text]</NOBR><!-- /HIGHWIRE --><!-- null --> <LI value=15>Herrick, C. A. & Bottomly, K. (2003) Nat. Rev. Immunol. 3, 405?412.<!-- HIGHWIRE ID="102:28:9866:15" -->[CrossRef][ISI][Medline] <!-- /HIGHWIRE --><!-- null --><LI value=16>Das, J., Chen, C. H., Yang, L., Cohn, L., Ray, P. & Ray, A. (2001) Nat. Immunol. 2, 45?50.<!-- HIGHWIRE ID="102:28:9866:16" -->[CrossRef][ISI][Medline] <!-- /HIGHWIRE --><!-- null --><LI value=17>Duran, A., Rodriguez, A., Martin, P., Serrano, M., Flores, J. M., Leitges, M., Diaz-Meco, M. T. & Moscat, J. (2004) EMBO J. 23, 4595?4605.<!-- HIGHWIRE ID="102:28:9866:17" -->[CrossRef][ISI][Medline] <!-- /HIGHWIRE --><!-- null --><LI value=18>Marsland, B. J., Soos, T. J., Spath, G., Littman, D. R. & Kopf, M. (2004) J. Exp. Med. 200, 181?189.<!-- HIGHWIRE ID="102:28:9866:18" --><NOBR>[Abstract/Free Full Text]</NOBR><!-- /HIGHWIRE --><!-- null --> <LI value=19>Cannons, J. L., Yu, L. J., Hill, B., Mijares, L. A., Dombroski, D., Nichols, K. E., Antonellis, A., Koretzky, G. A., Gardner, K. & Schwartzberg, P. L. (2004) Immunity 21, 693?706.<!-- HIGHWIRE ID="102:28:9866:19" -->[CrossRef][ISI][Medline] <!-- /HIGHWIRE --><!-- null --><LI value=20>Salek-Ardakani, S., So, T., Halteman, B. S., Altman, A. & Croft, M. (2004) J. Immunol. 173, 6440?6447.<!-- HIGHWIRE ID="102:28:9866:20" --><NOBR>[Abstract/Free Full Text]</NOBR><!-- /HIGHWIRE --><!-- null --> <LI value=21>Pfeifhofer, C., Kofler, K., Gruber, T., Tabrizi, N. G., Lutz, C., Maly, K., Leitges, M. & Baier, G. (2003) J. Exp. Med. 197, 1525?1535.<!-- HIGHWIRE ID="102:28:9866:21" --><NOBR>[Abstract/Free Full Text]</NOBR><!-- /HIGHWIRE --><!-- null -->
- Sun, Z., Arendt, C. W., Ellmeier, W., Schaeffer, E. M., Sunshine, M. J., Gandhi, L., Annes, J., Petrzilka, D., Kupfer, A., Schwartzberg, P. L. & Littman, D. R. (2000) Nature 404, 402?407.<!-- HIGHWIRE ID="102:28:9866:22" -->[CrossRef][ISI][Medline] <!-- /HIGHWIRE -->





Comment